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11 Abstract-Zusammenfassung 
Picornaviruses are small, non-enveloped, icosahedral viruses with an RNA genome of 
positive sense. The family is subdivided into nine genera that contain important human and 
animal pathogens. The genome contains only one large open reading frame from which a 
polyprotein is translated. This polyprotein is then processed by viral proteinases in order to 
obtain the mature viral proteins. The chymotrypsin-like proteinase 2Apro performs the initial 
cleavage of this processing in human rhinoviruses (HRV). It cleaves between the C-terminus of 
the preceding structural protein VP1 and its own N-terminus in an intramolecular (cis) 
reaction. In foot and mouth disease virus (FMDV), the first cleavage in polyprotein processing 
is performed by the leader protease (Lpro). This papain-like proteinase cleaves between its own 
C-terminus and the N-terminus of the structural protein VP4. Lpro was shown to be able to do 
so in both cis (intramolecular) or in trans (intermolecular) reactions. However, it has been 
found that the reaction is most likely intramolecular in vivo. 
Cells infected with HRVs or FMDV were found to be severely impaired in translation of 
their own capped mRNAs. This phenomenon, called the host cell shut-off, has been shown to 
be caused by either 2Apro (HRV) or Lpro (FMDV). Both of these proteinases were found to 
specifically cleave the host cell factor eukaryotic initiation factor 4G (eIF4G). eIF4G acts as a 
scaffolding protein in the translation initiation complex. Thus, the cell can no longer recruit its 
capped mRNAs to the 40S ribosomal subunit when eIF4G is cleaved. In contrast, viral RNA is 
uncapped and translation is initiated via an internal ribosomal entry segment (IRES). Therefore, 
translation of viral RNAs is still possible and the virus can take over the host cell translation 
machinery. 
The cleavage sites used in the self-processing reaction by HRV2 and HRV14 2Apro are 
not conserved. We show here that HRV2 2Apro is not able to accept the cleavage site of HRV14. 
The search for the minimal number of HRV14 residues that are able to cause this inability 
revealed that HRV14 residues at both sides of the cleavable bond are necessary to prevent 
HRV2 2Apro from processing and that proline at P2’ is important for HRV2 2Apro to recognize its 
substrate. Furthermore, we were able to show that substrate requirements in cis do not 
necessarily need to fit the requirements in trans. Cleavage sites that were found to be utilized 
by HRV2 2Apro in the cleavage of nuclear pore complex proteins could not be accepted in cis. 
In the crystal structure of HRV2 2Apro, the N-terminus is turned away from the active 
site and gives a picture of the protease after self-processing. Therefore, a rearrangement of 
the N-terminus will be needed to allow self-processing. It has been suggested that Met5 could 
act as a hinge at which the N-terminus is rotated into the active site. We speculated that this 
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rotation would bring the side chain of Met5 close to the positively charged side chain of Lys109 
and that for this reason an arginine could not be accepted at P5. However, we could show that 
this idea was false. Another approach aimed to help to understand the differences in substrate 
requirements of HRV2 and HRV14 2Apro and to reveal possible mechanistic differences in the 
self-processing of these two proteinases. For this purpose, we tried to construct active 2Apro 
hybrids made up of the N-terminal domain of HRV14 2Apro and the C-terminal domain of HRV2 
2Apro. Unfortunately, the 2Apro hybrids were totally inactive and therefore only little 
information could be obtained by these experiments. Finally, the influence of the protein 2B 
on 2Apro self-processing and on the different behavior of HRV2 and HRV14 2Apro in respect to 
the inhibitor zVAM.fmk was to be explored. We show here that self-processing is slightly 
delayed in the presence of 2B. As our zVAM.fmk stocks were found to be out of date, these 
experiments had to be postponed. 
In a last set of experiments, we investigated the S2 pocket of Lbpro. It has been shown 
that Leu143 is an important determinant in discriminating phenylalanine from protruding into 
the S2 pocket. Leu143 is not conserved amongst FMDV strains. Also methionine can be found 
at this position. Thus, we tested whether methionine was able to maintain this specificity. We 
were able to show that methionine exhibits similar ability to discriminate phenylalanine, 
indicating that not cleaving substrates with phenylalanine has biological relevance for the 
virus. 
  
 
13 Abstract-Zusammenfassung 
Picornaviren sind kleine Viren ohne Lipidhülle, die die Symmetrie eines Ikosaeders 
aufweisen. Die Familie der Picornaviren wird in neun Genera geteilt und enthält wichtige 
Pathogene für Mensch und Tier. Als Genom besitzen Picornaviren RNA mit positiver Polarität. 
Dieses besitzt nur einen offenen Leserahmen von dem ein Polyprotein abgelesen wird. Um die 
einzelnen viralen Proteine zu erhalten wird dieses von viralen Proteasen prozessiert. In 
humanen Rhinoviren (HRV) führt dabei die Chymotrypsin-ähnliche Protease 2Apro den ersten 
Schnitt durch. In einer intramolekularen (cis) Reaktion spaltet sie das Polyprotein zwischen 
dem C-Terminus des vorangehenden strukturellen Proteins VP1 und ihrem eigenen N-
Terminus. Die Prozessierung des Polyproteins der Maul-und-Klauenseuche (FMDV) wird von 
der Leader Protease (Lpro) eingeleitet. Diese Papain-ähnliche Protease spaltet das Polyprotein 
zwischen ihrem eigenen C-Terminus und dem N-Terminus des strukturellen Proteins VP4. Es ist 
bekannt, dass diese Reaktion prinzipiell in cis (intramolekular) oder trans (intermolekular) 
möglich ist. Allerdings wurde gezeigt, dass in vivo wahrscheinlich die intramolekulare Reaktion 
bevorzugt wird. 
Die Translation von zellulären gecappten mRNAs ist in HRV oder FMDV infizierten 
Zellen stark eingeschränkt. Dieses als Abschaltung der Wirtszelle bekannte Phänomen wird 
durch die Proteasen 2Apro (HRV) beziehungsweise Lpro (FMDV) verursacht. Beide sind fähig den 
eukaryotischen Initiationsfaktor 4G der Wirtszelle spezifisch zu spalten. Dieser arbeitet als 
Verbindungsprotein im Translationsinitiationskomplex. Durch die Spaltung dieses Proteins ist 
es der Wirtszelle nicht mehr möglich die eigenen gecappten mRNAs zur 40S Untereinheit der 
Ribosomen zu rekrutieren. Die virale RNA ist aber nicht gecappt. Ihre Translation wird intern 
über ein sogenanntes internes ribosomales Eintrittssegment (IRES) initiiert. Die Translation 
dieser viralen RNAs ist deshalb trotzdem möglich und der Virus übernimmt die Kontrolle über 
die Translationsmaschinerie der Wirtszelle. 
Die von HRV2 und HRV14 2Apro bei der Selbstprozessierung benutzten Schnittstellen 
sind nicht konserviert. Wie wir hier zeigen, kann die Schnittstelle aus HRV14 von HRV2 2Apro 
nicht akzeptiert werden. Die Suche nach der minimalen Anzahl an HRV14 Resten die dies 
verursachen ergab, dass HRV14 Reste auf beiden Seiten der Spaltstelle eingeführt werden 
müssen um HRV2 2Apro daran zu hindern die Schnittstelle zu erkennen. Außerdem wurde 
entdeckt, dass die Aminosäure Proline an Position P2‘ für die Erkennung des Substrates der 
HRV2 2Apro wichtig ist. Über dies hinaus konnten wir beweisen, dass die Anforderungen an das 
Substrat in der cis Reaktion nicht zwingendermaßen mit den Anforderungen der trans Reaktion 
übereinstimmen müssen. Schnittstellen die bei der Spaltung von Proteinen des nuklearen 
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Porenkomplexes in trans von HRV2 2Apro benutzt werden, wurden in der cis Reaktion nicht 
akzeptiert. 
In der Kristallstruktur von HRV2 2Apro ist der N-Terminus vom aktiven Zentrum 
weggedreht. Dies entspricht der Situation nach der Prozessierung in cis. Um die 
Selbstprozessierung aber möglich zu machen, muss der N-Terminus neu angeordnet werden. 
Es wurde bereits vorgeschlagen, dass Met5 als Angelpunkt fungieren könnte an dem der N-
Terminus in das aktive Zentrum gedreht wird. Dadurch würde die Seitenkette von Met5 nahe 
der positiv geladenen Seitenkette von Lys109 positioniert. Deshalb nahmen wir an, dass die 
Aminosäure Arginin an Position P5 von HRV2 2Apro nicht akzeptiert werden würde. Wir zeigen 
hier allerdings, dass diese Theorie falsch war. Ein weiteres Experiment sollte helfen, die 
Unterschiede in der Substratspezifität von HRV2 und HRV14 2Apro zu verstehen und zielte auch 
darauf ab, eventuell vorhandene mechanistische Unterschiede aufzuklären. Dabei versuchten 
wir aktive 2Apro Hybride zu konstruieren, die aus der N-terminalen Domäne der HRV14 2Apro 
und der C-terminalen Domäne der HRV2 2Apro bestehen. Unglücklicherweise waren diese 
Hybride vollständig inaktiv weshalb nur sehr wenig schlüssige Information aus diesen 
Experimenten gewonnen werden konnte. Schließlich sollte auch noch der Einfluss des Proteins 
2B auf die Selbstprozessierung der HRV2 und HRV14 2Apro und deren unterschiedliche Reaktion 
auf den Inhibitor zVAM.fmk getestet werden. Wir konnten zeigen, dass in Anwesenheit des 
Proteins 2B die Selbstprozessierung leicht verzögert abläuft. Unsere zVAM.fmk Bestände 
stellten sich aber leider als zu alt heraus, weshalb diese Experimente verschoben werden 
mussten. 
Abgesehen von diesen Experimenten wurde auch die S2 Tasche der Leader Protease 
(Lbpro) untersucht. Es wurde gezeigt, dass Leu143 eine wichtige Determinante ist um 
Phenylalanin nicht in diese Tasche eindringen zu lassen. Leu143 an dieser Position ist aber 
nicht unter allen FMDV Stämmen konserviert. Manche Stämme besitzen auch Methionin an 
dieser Stelle. Deshalb  testeten wir, ob auch Methionin diese Aufgabe erfüllen kann. 
Tatsächlich konnten wir zeigen, dass auch Methionin fähig ist, Phenylalanin aus der S2 Tasche 
zu verdrängen. Diese Fakten legen nahe, dass es von biologischer Relevanz für den Virus ist, 
Substrate mit Phenylalanin an P2 nicht zu spalten. 
2 INTRODUCTION 
  
 
17 Introduction 
2.1 PICORNAVIRUSES  
Picornaviruses are small (30nm diameter), non-enveloped, icosahedral viruses with a 
RNA genome of positive sense. The name originates from its small size (pico) and the nature of 
its genome. The family contains several important human and animal pathogens such as 
poliovirus (PV), human rhinoviruses (HRV), hepatitis A virus (HAV) and foot and mouth disease 
virus (FMDV). The family is subdivided into nine genera named enterovirus, rhinovirus, 
cardiovirus, aphthovirus, hepatovirus, parechovirus, erbovirus, kobuvirus and teschovirus 
(Fauquet 2005). Recently, the international committee on taxonomy of viruses (ICTV) reported 
the reclassification of the genus rhinovirus into the genus of enterovirus (ICTV 2008), reducing 
the number of picornaviral genera to eight.  
This thesis discusses experiments with the proteinases 2Apro of human rhinoviruses 
and Lbpro of FMDV. Therefore, the introduction is focused on the genera of rhinoviruses and 
aphthoviruses. Nevertheless, several unifying principles of picornaviruses were examined on 
PV that acts as a role model. Therefore, many references refer to experiments with this 
enterovirus. 
2.2 HUMAN RHINOVIRUSES 
Human rhinoviruses (HRV) are the main causative agent of the common cold (Makela 
et al. 1998). The sites of infection are the nose and the throat, explaining the name of the 
genus (Arruda et al. 1997). Common colds are one of the main reasons for short time absence 
from work and cause enormous economic loss (Savolainen et al. 2002). Moreover, HRVs were 
also reported to cause more severe diseases and were recently connected with severe 
respiratory-tract infection in children (Renwick et al. 2007). Neither vaccines nor anti-viral 
compounds are available for the control and treatment of HRVs. 
2.2.1 TAXONOMY 
In 2005, the international committee on taxonomy reported a total of 103 HRV 
serotypes (Fauquet 2005). There are two systems for classifying HRVs. The first one uses 
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sequence homologies in the capsid proteins VP1 and VP4 to cluster the serotypes into either 
genetic group A or B (Laine et al. 2006). Recently, Lau et al. reported the discovery of a new 
genetic cluster C that is associated with acute respiratory illness in children (Lau et al. 2007). 
The second classification system groups the serotypes based on the receptor used for 
attachment and entry. About 90% of all serotypes belong to the so called major group viruses 
that use the intercellular adhesion molecule 1 (ICAM-1) as a receptor (Greve et al. 1989, 
Staunton et al. 1989). The remaining serotypes use the low density lipoprotein receptor (LDLR) 
or another member of the LDLR family (Hofer et al. 1994) and belong to the so-called minor 
group of human rhinoviruses. 
2.3 FOOT-AND-MOUTH DISEASE VIRUS 
FMDV is an animal pathogen of global interest (Kitching 2005). It infects cloven-hoofed 
animals such as cattle, swine, sheep, goats or deer. The symptoms of the infection range from 
fever and lameness to vesicular lesions on the tongue, snout, feet and teats. FMDV is ranked 
amongst the most highly contagious pathogens of animals. Infection occurs via the respiratory 
route (Donaldson et al. 1987) or lesions of the skin or mucous membranes (Donaldson 1987). 
Virus is also shed via milk (Hyde et al. 1975) as well as semen, urine and feces (Donaldson 
1987). Control strategies include mass slaughter and quarantine of areas in which an FMDV 
outbreak has been recognized. An effective vaccine is available (Bahnemann 1975) and was 
used for successful control in Western Europe. However, an effective anti-viral compound is 
desirable for regions that have been reported free of FMDV for a longer time and for the 
treatment of persistently infected animals. 
2.3.1 TAXONOMY 
The species FMDV belongs to the genus of aphthoviruses and is subdivided into seven 
serotypes: A, O, C, Asia 1 and South African Territories 1, 2 and 3. Each of these serotypes 
contains a number of subtypes (Fauquet 2005). 
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2.4 THE VIRION 
2.4.1 CAPSID 
The picornaviral capsid is made up of four structural proteins named VP1-VP4 (the 
term VP0 resembles a precursor that is cleaved into the two proteins VP4 and VP2). The 
building block of the capsid is the protomer that consists of one copy of each structural protein 
(Figure 2-1A). 60 of these protomers can be combined to build up a picornaviral capsid. Several 
cryo-EM and X-ray structures of picornaviral capsids are available. The first structure of a 
picornaviral capsid to be solved was the one of HRV14 (Rossmann et al. 1985). Structures of 
PV1 (Hogle et al. 1985), FMDV serotype O (Acharya et al. 1989), HRV16 (Oliveira et al. 1993) 
and coxsackievirus B3 (CVB3) (Muckelbauer et al. 1995) followed. All these structures revealed 
that picornaviral capsids are of icosahedral symmetry with a triangulation number of T=3 
(Figure 2-1A). VP1-VP3 form the outer shell, while VP4 is hidden in the interior. 
 
 
Figure 2-1 Structural features of picornaviral capsids. (A) Schematic representation of 
the capsid. The protomer with one copy of each structural protein is colored in grey (VP4 lies in the 
interior and cannot be seen). Five protomers build up a pentamer (light blue) (Fields et al. 2007). (B) X-
ray structure of PV1. A 5-fold axis is labeled with “5x” and the canyon surrounding it is indicated by the 
arrow (Hogle et al. 1985). (C) Cryo-EM reconstruction of PV1. The star-shaped plateau at each 5-fold axis 
is surrounded by the 12Å deep canyon (Fields et al. 2007). 
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VP1, VP2 and VP3 share no sequence homology. Nevertheless, they all fold into a 
wedge shaped structure that is made up of an eight stranded antiparallel β-barrel. This barrel 
consists of two antiparallel β-sheets (Figure 2-2). Tight protein packing allows a number of 
protein-protein contacts enabling the assembly of a stable capsid. The C-termini of the 
structural proteins are exposed to the exterior of the shell while the N-termini are buried in 
the interior. 
 
 
Figure 2-2 Secondary structure elements of the picornaviral structural proteins. The two 
antiparallel β-sheets form a wedge shaped β-barrel (Burke et al. 1991). 
The capsid surface of rhinoviruses and enteroviruses exhibits plateaus at the 3-fold and 
5-fold axes of symmetry. The 5-fold axis is surrounded by a deep cleft called the canyon (Figure 
2-1B and C) which has been proven to be the receptor binding site for major group HRVs (see 
section 2.5.1.1). This canyon is not found on the surface of FMDV. It is filled by an insertion 
between the two β-strands βG and βH (Semler and Wimmer 2002). Another unique feature of 
FMDV capsids is the presence of a pore at the five-fold axis through which small molecules can 
pass (Acharya et al. 1989). The capsids of HRVs and FMDV are acid labile and therefore cannot 
pass the intestinal tract as PV (Fields et al. 2007). 
2.4.2 GENOME 
Picornaviruses have a single stranded RNA of positive polarity as their genome. The 5’ 
uncapped and 3’ polyadenylated RNA varies in length from about 7.1kb for HRVs to about 
8.1kb for FMDV (Figure 2-3) (Stanway et al. 1984, Skern et al. 1985, Beard and Mason 2000). 
The viral protein VPg is covalently linked to the 5’ end of picornaviral genomes (Lee et al. 
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1977). A long 5’ untranslated region (UTR) is followed by a single, approximately 6.5-6.9kb long 
open reading frame (ORF). The 3’ UTR is short (e.g. 47bp in HRV14) followed by the poly-A tail 
that is required for infectivity (Spector and Baltimore 1974). Both untranslated regions contain 
highly ordered structures that are involved in replication of the genome and initiation of cap 
independent translation (see sections 2.5.3 and 2.5.5). 
 
 
Figure 2-3 Picornaviral genome organization. (A) HRV. (B) FMDV. The single ORF is 
flanked by untranslated regions containing highly ordered structures. The RNA has the viral protein VPg 
covalently linked to its 5’ end and is polyadenylated at its 3’ end. The coding region is arranged in three 
regions called P1-P3. In FMDV the P1 region is preceded by the coding region for the L protein. (Fields et 
al. 2007) 
The open reading frame is organized in three regions designated P1-P3. P1 contains 
the four structural proteins VP1-VP4. The protease 2Apro and the accessory proteins 2B and 2C 
are encoded in region P2 while the P3 region codes for accessory proteins as well as the 
protease 3Cpro and the polymerase 3Dpol. In contrast to HRVs, FMDV codes for an additional 
protein, the so called leader protease (L). The coding region for this protein precedes the P1 
region of structural proteins. 
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2.5 LIFE CYCLE 
 
Figure 2-4 Schematic overview of the viral life cycle. After attachment and entry (1) the 
genome is released into the cytoplasm (2). VPg is cleaved off and the ORF is translated into a long 
polyprotein (3). This polyprotein is then proteolytically processed by viral proteinases (4). Once the 
polymerase is synthesized, viral minus strand RNA intermediates are produced (5) which serve as 
template for the production of several new positive strands (6). These new strands are either used for 
further translation (7) or packed into new particles (8). The virus is then released from the cell upon cell 
lysis (9) (Fields et al. 2007). 
2.5.1 ATTACHMENT AND ENTRY 
2.5.1.1 ATTACHMENT AND ENTRY OF HUMAN RHINOVIRUSES 
HRVs can be classified into the major and minor group based on the cellular receptor 
used for attachment and entry. Major group HRVs use the intercellular adhesion molecule 1 
(ICAM-1) (Greve et al. 1989, Staunton et al. 1989) whereas minor group viruses use the low 
density lipoprotein receptor (LDLR) or other members of the LDLR family (low density 
lipoprotein receptor-related protein LRP or very low density lipoprotein receptor VLDLR) 
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(Hofer et al. 1994, Marlovits et al. 1998b). After attachment to the cell, the virus is taken up via 
endocytosis (Schober et al. 1998). 
ICAM-1 is a member of the immunoglobulin superfamiliy. It is a transmembrane 
protein with a short intracellular, C-terminal domain (Staunton et al. 1988). The extracellular, 
N-terminal part of the protein consists of five immunoglobulin-like domains designated D1-D5 
and is highly glycosylated. Its natural function is to bind the ligands leukocyte function-
associated antigen-1 (LFA-1) and macrophage-1 antigen (Mac-1) at sites of infection.  
The first atomic structure of an HRV particle (HRV14) revealed that a star shaped 
plateau at each five-fold axis of the icosahedral capsid is surrounded by a 12Å deep depression 
named the canyon (Figure 2-1B and C) (Rossmann et al. 1985). Soon, it was suggested that this 
12-15Å wide canyon with its conserved residues at the floor could be the site of receptor 
binding. This theory was further strengthened by the finding that mutating residues at the 
canyon floor resulted in altered binding levels (Colonno et al. 1988). Finally, cryo-EM data of 
receptor-virus complexes showed that the canyon was indeed the site of receptor binding 
(Figure 2-5) (Olson et al. 1993). ICAM-1 was shown to bind the central region of the canyon of 
HRV16 with its N-terminal domain D1 penetrating about 10Å deep into the canyon. 
 
 
Figure 2-5 Cryo EM reconstruction of HRV16 bound to a recombinant fragment of ICAM-
1. (A) Five molecules of the receptor bind to the canyon surrounding the plateau at each fivefold axis. 
(B) Schematic representation of the D1 domain of ICAM-1 binding to the floor of the canyon of the viral 
particle. (Olson et al. 1993). 
The entry pathway of major group viruses is not yet completely understood. HRVs that 
use the canyon for receptor binding are destabilized upon binding. It has been shown that 
receptor binding alone is sufficient to induce conformational changes in the capsids of HRV14 
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and HRV16 (Hoover-Litty and Greve 1993). Binding of the D1 domain of ICAM-1 is thought to 
cause VP1 to slide slightly apart from the five-fold axis opening a channel through which the 
RNA could possibly be released (Kolatkar et al. 1999). This model is consistent with kinetic 
studies about the binding of the virus to the receptor. Nevertheless, also different entry modes 
are possible.  
The LDLR family consists of proteins that contain variable numbers of repeats that are 
about 40 amino acids in length (so called “complement type A repeats”) (Yamamoto et al. 
1984). The number of this repeats varies among different family members. LDLR is responsible 
for the binding and internalization of lipids that are transported in apolipoprotein complexes B 
or E into the cell. LDLR, which is strongly conserved through evolution, was found to serve as 
receptor for minor group HRVs. 
The first hints in discovering the minor group receptor were obtained from binding 
experiments of HRV2 to detergent solubilized HeLa cell membranes. Mischak et al. showed 
that HRV2 could specifically bind a protein that was about 120 kDa in size (Mischak et al. 
1988). This protein was further investigated by trypsin digestion, and N-terminal amino acid 
sequencing identified the protein as being human LDLR (Hofer et al. 1994).  Marlovits et al. 
showed that recombinant LDLR was able to protect HeLa cells from infection with minor 
groups viruses, whereas HRV14 infection was unaffected (Marlovits et al. 1998c). Cryo-EM of 
recombinant VLDLR fragments complexed to HRV2 showed that the receptor binds at the star 
shaped plateau that is surrounded by the canyon (Figure 2-6) (Hewat et al. 2000). 
Furthermore, it was shown that already two of the complement type A repeats are sufficient 
to bind the virus (Marlovits et al. 1998a). 
 
 
Figure 2-6 Cryo EM reconstruction of HRV2 bound to a VLDLR fragment. The receptor 
binds close to the five-fold axis of symmetry and builds up a ring-structure at the plateau (Hewat et al. 
2000). 
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The uptake of the minor group HRV2 was shown to be much faster than the uptake of 
the major group HRV14 (Lonberg-Holm and Korant 1972). This is thought to be due to the lack 
of an internalization signal on ICAM-1. Still, HRV14 is dependent on an intact clathrin-
dependent endocytosis pathway which suggests the involvement of a co-receptor (DeTulleo 
and Kirchhausen 1998). In contrast to major group HRVs, minor group HRVs are not 
destabilized upon receptor binding. They are therefore strongly dependent on the low pH that 
arises in the endosomes (Neubauer et al. 1987, Prchla et al. 1994) whereas HRV14 is able to 
uncoat in the presence of the drug bafilomycin A1 which blocks acidification of the endosomes 
(Schober et al. 1998, Bayer et al. 1999). 
2.5.1.2 ATTACHMENT AND ENTRY OF FMDV 
Early experiments showed that trypsin treatment of FMDV results in virus particles 
that are unable to bind cells (Moore and Cowan 1978). Subsequently, it was found that trypsin 
cleaves the capsid protein VP1 at position Arg144 (Robertson et al. 1983). This finding led to 
the speculation that this region may be involved in receptor binding. In 1984, Pierschbacher 
and Ruoslahti found that the tri-peptide ArgGlyAsp served as the recognition site for the 
fibronectin-receptor (Pierschbacher and Ruoslahti 1984b), a member of the integrin family. 
Interestingly, this RGD-sequence was also found in FMDV VP1 (Pierschbacher and Ruoslahti 
1984a) and turned out to be a highly conserved motif (Pfaff et al. 1988). 
Further experiments showed that peptides containing this motif were able to inhibit 
the binding of the virus to the cells (Fox et al. 1989, Baxt and Becker 1990), and site directed 
mutagenesis of the RGD-motif strengthened the idea of its involvement in the attachment of 
FMDV even further (Leippert et al. 1997). Finally, integrin αVβ3  was proven to be the receptor 
utilized by FMDV (Berinstein et al. 1995, Neff et al. 1998, Neff et al. 2000, Neff and Baxt 2001). 
However, it has also been shown that some FMDV strains can use heparan sulfate as a co-
receptor (Jackson et al. 1996). 
The exact route of entry and mode of uncoating of FMDV is still unclear. There is 
evidence that the virus is probably taken up into endosomes, followed by a breakdown of the 
capsid via acidification of the endosomes (Carrillo et al. 1984, Carrillo et al. 1985, Baxt 1987). 
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2.5.2 DECODING OF THE GENETIC INFORMATION AND POLYPROTEIN PROCESSING 
Picornaviruses replicate in the cytoplasm of the host cell. Upon release of the viral RNA 
into the cytoplasm, the genome has to be translated before RNA replication can take place as 
the virus does not take its RNA dependent RNA polymerase with it. The viral RNA lacks a 5’ cap 
structure but has the viral protein VPg covalently linked to its 5’ end. However, it has been 
shown in PV that VPg is cleaved off by a cellular enzyme before translation can occur (Ambros 
and Baltimore 1980). Lacking the 5’ cap structure, translation has to be initiated by a different 
mechanism. The 5’ UTR of picornaviral genomes are 624 to 1119 nucleotides in length and 
contain highly structured regions (Fields et al. 2007). These structures are conserved among 
several members of picornaviruses, although they do not share sequence homology (Rivera et 
al. 1988). Deletions and mutations in this region of the genome were proven to effect 
translation (Bienkowska-Szewczyk and Ehrenfeld 1988, Trono et al. 1988), indicating that the 
secondary structures of the 5’ UTR are involved in a cap independent internal translation 
initiation. The structures responsible for binding the 40S subunit of the ribosome were termed 
internal ribosomal entry segment (IRES). The mechanism of translation initiation will be 
discussed in section 2.5.5 in more detail in the context of the host cell shutoff. 
Only one open reading frame is found on picornaviral genomes. Therefore, a large viral 
polyprotein is translated from this open reading frame. This polyprotein has to be processed 
by viral proteinases that specifically cleave the polypeptide chain to give the mature viral 
proteins. However, as the polyprotein is processed co-translationally (Toyoda et al. 1986), the 
whole polyprotein can never be detected. 
In HRVs, the protease 2Apro performs the initial cleavage on the polyprotein, cleaving 
between its own N-terminus and the C-terminus of the preceding structural protein VP1 
(Figure 2-7A) (Toyoda et al. 1986). HRV2 2Apro cleaves at the sequence IITTA*GPSD whereas 
HRV14 2Apro uses the cleavage site DIKSY*GLGP. 
The leader protease initiates polyprotein processing in FMDV by cleaving between its 
own C-terminus and the N-terminus of VP4 (Figure 2-7B) (Strebel and Beck 1986). The cleavage 
site used by the strain O1k (the strain used in the experiments) is RKLK*GAGQ. Interestingly, 
initiation of protein synthesis can occur on two different AUG codons that are separated by 28 
amino acids leading to the formation of two different forms of the L protease: Labpro and Lbpro 
(Sangar et al. 1987). Although both forms have the same enzymatic activity (Medina et al. 
1993), Lbpro is the form predominantly produced in infected cells (Cao et al. 1995). The protein 
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2A of FMDV is only 18 amino acids in length and does not have proteolytical activity. 
Nevertheless, it has been shown that this sequence causes the interruption of the polyprotein 
chain between its own C-terminus and the N-terminus of 2B by a putative ribosomal skip (Ryan 
et al. 1991, Donnelly et al. 2001). 
 
 
Figure 2-7 Schematic representation of the viral polyprotein of (A) HRV and (B) FMDV. 
The initial cleavages performed by 2Apro, Lpro and 3Cpro are indicated by arrows. 2Apro cleaves between 
the C-terminus of VP1 and its own N-terminus, Lpro cleaves between its own C-terminus and the N-
terminus of VP4 whereas 3Cpro performs its initial cleavage between 2C and 3A (Fields et al. 2007). 
All other cleavages are carried out by the proteinase 3Cpro or its precursor 3CDpro. 3Cpro 
and 3CDpro cleave between the amino acids glutamine and glycine. However, glutamine and 
glycine do not seem to be the only substrate requirements for 3Cpro as only nine of thirteen 
Gln*Gly junctions are cleaved in the PV polyprotein (Kitamura et al. 1981, Hanecak et al. 1982). 
The last event in polyprotein processing is the cleavage of VP0 into VP4 and VP2. VP0 is 
cleaved in the already assembled new viral particle in a maturation step. The mechanism of 
this cleavage remains unclear. The theory that the conserved Ser10 of VP2 could be 
responsible for the cleavage (Arnold et al. 1987) was discarded after it was found that 
mutating Ser10 to alanine did not affect cleavage. Subsequently, a conserved histidine was 
thought to act together with the RNA to cleave VP0 (Curry et al. 1997). 
2.5.3 REPLICATION OF THE GENOME 
A critical concentration of 3CDpro is thought to initiate the switch from translation to 
negative strand RNA synthesis (Gamarnik and Andino 1998). Replication of the picornaviral 
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RNA genome is a highly complex process in which all but the structural proteins of the virus are 
involved. In infected cells, the bulk of the cytoplasm is occupied by virus induced membranous 
vesicles (Bienz et al. 1990) at which the RNA genome is replicated. Replication is performed by 
a viral encoded RNA dependent RNA polymerase which also covalently links the RNA to Tyr3 of 
VPg (Gerber et al. 2001a). As the polymerase cannot initiate RNA synthesis on a naked RNA 
strand, VPg serves as a primer (Gerber et al. 2001b). Recently, a model of the minus strand 
synthesis mechanism has been proposed in which the genome undergoes circularization by 
involvement of the cellular poly-A binding protein (PABP) (Herold and Andino 2001). Once a 
minus strand RNA has been produced by the polymerase, it serves as an intermediate for the 
production of several new positive strands (Novak and Kirkegaard 1991). No free minus 
strands are however observed in the cell. They are only found in an either fully double 
stranded replicative form or a replicative intermediate that consists of a full length minus 
strand coupled to a various number of complementary positive strands. While the viral 
polymerase can copy any primed RNA in vitro, it is known that in vivo it only replicates viral 
RNA. Structural patterns in the viral RNA such as the cloverleaf in the 5’ UTR (Rivera et al. 
1988), a single stem loop in the 3’ UTR (Pilipenko et al. 1992) or internal cis-acting elements 
(Gerber et al. 2001a) ensure that the viral RNA is specifically recruited to the replicative 
complex. 
2.5.4 ASSEMBLY AND VIRUS RELEASE 
Assembly of the virus is a highly specific process in which only viral positive stranded 
RNA that is linked to VPg is encapsidated (Novak and Kirkegaard 1991). It is thought that this 
specificity is achieved by coupling the process of packing to the synthesis of positive stranded 
RNA (Halperen et al. 1964). Folding of the structural proteins starts co-translationally. Once 
HRV 2Apro or FMDV 2A has separated them from the non-structural proteins, 3Cpro cleaves 
between VP0-VP3 and VP3-VP1 leading to the formation of the 5S protomer. The 5S protomer 
is the structural building block of the capsid containing one copy of each protein VP0, VP3 and 
VP1. Subsequently, 5 protomers assemble to build the 14S pentamer (Figure 2-8) (Palmenberg 
1982). These important intermediates are capable of self-assembly to form an empty 80S 
capsid. There are two possible ways of packing the RNA into the capsid. Jacobson et al. stated 
a model in which RNA is inserted into fully built empty capsids (Jacobson and Baltimore 1968). 
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The second model claims that the RNA assembles with the 14S pentamers which then build up 
the provirion with the already encapsidated RNA (Nugent and Kirkegaard 1995). Finally, VP0 is 
cleaved by a yet unknown mechanism resulting in higher stability of the particle and 
acquisition of infectivity (Basavappa et al. 1994). Virus is then released from the cell upon cell 
lysis. 
 
 
Figure 2-8 Assembly of the viral particle. Five protomers are combined to form a 
pentamer. This structure is capable of self-assembly to form an empty capsid. Whether the genome is 
inserted into a fully built capsid or is encapsidated while the particle is built up is still under debate. 
Finally VP0 is cleaved by an yet unknown mechanism in a maturation step (Rotbart 1995). 
2.5.5 HOST CELL SHUTOFF 
The so called host-cell shutoff is a phenomenon in which infected cells can no longer 
produce their own proteins (Etchison et al. 1982, Etchison and Fout 1985, Devaney et al. 
1988). In contrast, viral proteins are still produced allowing the virus to take over its host-cell. 
However, the host-cell’s mRNAs have been shown to be maintained intact. Therefore, the key 
event of this phenomenon has to be found in the process of translation. 
Cellular mRNAs are 7-methyl-guanosine capped at their 5’ end. This cap structure is 
important for the so-called 43S preinitiation complex (containing the 40S subunit of the 
ribosome) to recruit an mRNA. Subsequently, the 40S subunit scans for the AUG initiation 
codon, the 60S subunit of the ribosome binds and translation can occur. The recognition of the 
mRNA is mediated by several initiation factors (Figure 2-9A). Eukaryotic initiation factor 4E 
(eIF4E, also called cap binding protein) is capable of binding the cap structure of the mRNA 
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(Sonenberg et al. 1978). Additionally, it has a binding site for the N-terminal domain of 
eukaryotic initiation factor 4G (eIF4G) (Mader et al. 1995). eIF4G consists of two domains and 
acts as a central scaffolding protein for the initiation complex. With its C-terminal domain, it 
binds eukaryotic initiation factor 4A (eIF4A) and eukaryotic initiation factor 3 (eIF3) that in turn 
binds the 40S subunit of the ribosome (Lamphear et al. 1995). An additional site on the N-
terminal domain of eIF4G binds poly-A binding protein (PABP), leading to a circularization of 
the complex (Imataka et al. 1998). The complex of eIF4A, eIF4G and eIF4E is called eIF4F. 
Figure 2-10 gives a schematic representation of the eIF4G binding domains. 
 
 
Figure 2-9 Schematic illustration of the initiation factors involved in cap-dependent and 
cap-independent translation initiation. (A) eIF4G acts as a scaffolding protein to bring together the 
capped mRNA and the 40S subunit of the ribosome. (B) eIF4G cleavage by 2Apro or Lpro renders the 
complex unable to recruit capped RNA. However, viral RNAs can still be translated by cap-independent 
initiation via an internal ribosomal entry segment (IRES) (Fields et al. 2007). 
It was first shown in PV infected HeLa cells that the initiation factor eIF4G is cleaved 
during the host-cell shut-off (Etchison et al. 1982). This leads to the loss of eIF4Gs scaffolding 
function and therefore to the loss of eIF4Fs ability to recruit capped mRNAs to the 40S subunit 
of the ribosome. However, viral RNAs initiating on an IRES are still able to be translated (Figure 
2-9B). It has been shown that initiation of translation from an IRES works even more efficiently 
in the presence of the C-terminal cleavage product of eIF4G than in the presence of intact 
eIF4G (Borman et al. 1997). Thus, the virus is gaining advantage over the host cell.  
The enzyme responsible for the cleavage of eIF4G in human rhinovirus infected cells 
was found to be the viral protease 2Apro. Lamphear et al. showed that 2Apro of HRV2 was 
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capable of directly cleaving eIF4G (Lamphear et al. 1993). In contrast, in FMDV infected cells 
eIF4G is cleaved by the leader protease (Devaney et al. 1988). In 1998, Gradi et al. reported 
the discovery of a homologue of eIF4G termed eIF4GII while the original protein was renamed 
eIF4GI (Gradi et al. 1998b). The two homologues share only 46% amino acid identity. 
Nevertheless, it has been shown that both homologues have to be cleaved to lead to the host 
cell shut-off (Gradi et al. 1998a). The cleavage sites of HRV2 2Apro have been mapped as 
LSTR681*GPPR at eIF4GI (Lamphear et al. 1993) and LLNV699*GSRR at eIF4GII (Gradi et al. 2003). 
The leader protease has been shown to cleave these two isoforms at FANLG674*RTTL (eIF4GI) 
and LLNVG700*SRRS (eIF4GII) (Kirchweger et al. 1994, Gradi et al. 2004) (Figure 2-10). 
 
 
Figure 2-10 Organization of the scaffolding protein eIF4G. The binding domains for PABP, 
eIF4E, eIF4A, eIF3 and Mnk as well as the cleavages sites used by HRV2 2Apro and FMDV Lbpro are shown 
(Zhao et al. 2003). 
2.6 2APRO 
2.6.1 FUNCTION 
The first cleavage performed by 2Apro is the self-processing reaction in which it cleaves 
between the C-terminus of VP1 and its own N-terminus (Toyoda et al. 1986). The reaction is 
carried out co-translationally and in cis, freeing the structural proteins from the nonstructural 
ones. Subsequently, 2Apro cleaves the two homologues of eIF4G leading to the host-cell shut-
off. Besides this most important trans-cleavage, 2A proteinases of different picornaviruses 
were shown to cleave several other cellular proteins such as poly-A binding protein (Joachims 
et al. 1999, Kerekatte et al. 1999), dystrophin (Badorff et al. 1999), cytokeratin 8 (Seipelt et al. 
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2000) and members of the nuclear pore complex protein family (NUPs) (Gustin and Sarnow 
2001, Park et al. 2008) (Table 2-1). 
 
Protein Cleaved by 
PABP PV 2Apro and 3Cpro; CVB3 2Apro 
Dystrophin CVB3 2Apro 
Cytokeratin 8 HRV2 2Apro; CVB4 2Apro 
NUP98 HRV2 2Apro 
NUP62 HRV2 2Apro 
Table 2-1 Cellular proteins cleaved by picornaviral 2A proteinases. 
2.6.2 STRUCTURE 
Experiments with inhibitors revealed that 2Apro is a member of the cysteine 
proteinases (Konig and Rosenwirth 1988) and modeling led to the prediction that it has a 
chymotrypsin-like fold (Bazan and Fletterick 1988). Only two atomic structures of picornaviral 
2A proteinases are available at present. These are the crystal structure of HRV2 2Apro (Petersen 
et al. 1999) (Figure 2-11) and the NMR structure of coxsackievirus B4 2Apro (Baxter et al. 2006). 
Petersen et al. showed that HRV2 2Apro indeed has a chymotrypsin-like fold but also shows 
some major differences to the structure of chymotrypsin (a prototypic serine proteinase). 
HRV2 2Apro is made up of an N-terminal and a C-terminal domain connected by an 
interdomain-loop. The N-terminal domain is made up of four β-strands that form a β-sheet. 
This is one of the major differences to the structure of chymotrypsin with its eight β-strands in 
the N-terminal domain. The C-terminal domain is constructed of six β-strands that form a β-
barrel. This domain contains a zinc ion which is co-ordinated by the 3 sulfurs of Cys52, Cys54 
and Cys112 and the nitrogen of His114. However, this zinc ion is not involved in the catalytic 
activity. It is more likely thought to have an important role for the integrity of the structure 
(Sommergruber et al. 1994, Voss et al. 1995) by compensating the truncation of the N-terminal 
domain. The catalytic triad is made up of Cys106 (the nucleophile), His18 (the general base) 
and Asp35. Mutational analysis of these residues confirmed their role in catalysis 
(Sommergruber et al. 1997). 
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Figure 2-11 Overall structure of HRV2 2Apro. The two domains are highlighted in light blue 
(N-terminal) and dark blue (C-terminal), respectively. The zinc ion is depicted in purple. The catalytic 
triad Cys106, His18 and Asp35 is rendered as stick-model (Petersen et al. 1999). 
2.6.3 SUBSTRATE SPECIFICITY 
To date, most of the work done on substrate specificity of 2Apro has been performed 
with synthetic peptides. Only limited data is available from self-processing reactions. The only 
well conserved residue in HRV 2Apro cleavage sites is Gly at position P1’ (the nomenclature 
used here is the one of Berger and Schechter 1967). Consequently, peptides with Glu, Lys, Thr, 
Trp, Phe or Asp at P1’ are not cleaved (Skern et al. 1991, Sommergruber et al. 1992) by HRV2 
2Apro, confirming the strong requirement for Gly at P1’. However, recently it has been shown 
that HRV2 2Apro is able to cleave substrates with Ala at P1’ in trans (Gustin K., pers. comm.). 
Another determinant of substrate specificity of HRV2 2Apro is the residue at P2’. Peptides with 
Phe, Thr, Asp or Lys at P2’ were cleaved about 2-5 fold less efficiently by HRV2 2Apro than 
peptides with the wild-type proline (Sommergruber et al. 1992).  
At the C-terminal end of VP1, the residues at P2 and P4 play an important role in 
substrate specificity. Experiments with peptides show that HRV2 2Apro has a strong preference 
for Thr at P2. All peptides with differing residues at P2 were poorly recognized or not cleaved 
at all (Sommergruber et al. 1992). A substrate binding model by Petersen et al. (Figure 2-12A) 
may give an explanation for these results (Petersen et al. 1999). Threonine at P2 was found to 
form a hydrogen bond with Ser83. However, Tyr85 is found to stack on His18 and would have 
to rotate away from this stacked position in order to allow substrate binding (Figure 2-12B). 
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The formation of the hydrogen bond between threonine at P2 and Ser83 is thought to 
compensate for this rotation. The model also suggests that the narrowness and hydrophobicity 
of the S4 site is responsible for the preference for flexible hydrophobic residues at P4 (Figure 
2-12A). At position P1, a number of residues can be accepted by HRV2 2Apro. Met or Tyr at P1 
even enhance the efficiency of cleavage. Peptides with Arg at P1 were processed with a 
relative efficiency of 0.56 with respect to a peptide corresponding to the wt cleavage site. This 
correlates well with the acceptance of the cleavage site TLSTR*GPPR found on eIF4GI. 
Recently, it was shown that this cleavage site can also be processed in the self-processing 
reaction by HRV2 2Apro with only slight delays in kinetics (Sousa et al. 2006). 
 
 
Figure 2-12 HRV2 2Apro substrate binding model. A peptide representing the self-
processing substrate from P5-P1’ (IITTA*G) has been modeled into the substrate binding cleft of the 
HRV2 2Apro structure. (A) Stereo drawing of the model. The enzyme is represented with its surface 
colored by atom type. Residues 82-89 have been removed to enable a better view on the substrate (pink 
stick model). (B) Recognition of the P2 residue. Both molecules in the structure are shown by a 
superimposition on each other. Threonine at P2 is able to form a hydrogen bond with Ser83. Tyr85 
clashes with threonine at P2 and has to be rotated in order to allow substrate binding (Petersen et al. 
1999). 
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Less is known about the specificity of HRV14 2Apro. Experiments with recombinant 
HRV14 2Apro and peptides revealed that HRV14 2Apro accepts a peptide resembling its own 
polyprotein cleavage site very poorly. Interestingly, introduction of Pro at P2 improved the 
efficiency by more than tenfold. Furthermore, a peptide corresponding to the HRV2 2Apro wild-
type cleavage site was accepted even better (Wang et al. 1998). In contrast to HRV2 2Apro, 
HRV14 2Apro cannot process the eIF4GI site in cis (Sousa et al. 2006). Site directed mutagenesis 
showed that Arg at P1 is one of the residues preventing the HRV14 2Apro from processing this 
site. Mutating Ala 104 to Cys or Ser was sufficient to restore some activity, but not to wild-type 
levels. 
2.7 LPRO 
The translation of the FMDV polyprotein can be initiated on two start codons 
separated by 84 nucleotides. Thus, the leader proteinase exists in a full length (Labpro) and a 
shorter version (Lbpro) (Sangar et al. 1987). Although the two forms have been shown to have 
the same enzymatic activity (Medina et al. 1993), Lbpro was the form shown to be 
predominantly produced in the infected cell (Cao et al. 1995). Therefore, the experiments 
described in this thesis were performed with the shorter version, Lbpro. 
2.7.1 FUNCTION 
In the initial cleavage event of the FMDV polyprotein processing, Lpro frees itself from 
the growing polypeptide chain by cleaving between its own C-terminus and the N-terminus of 
VP4 (Strebel and Beck 1986). It has been shown that this reaction can be catalyzed in cis as 
well as in trans (Belsham et al. 1990, Medina et al. 1993, Piccione et al. 1995). However, Glaser 
et al. have presented data which strongly suggests that self-processing occurs in cis (Glaser et 
al. 2001). Subsequently Lpro, like 2Apro, cleaves the cellular translation initiation factor eIF4G 
(Devaney et al. 1988, Kirchweger et al. 1994, Gradi et al. 2004), therefore being responsible for 
the host cell shut off in FMDV infected cells. No other substrates have been identified so far. 
However, a recent study revealed that Lpro is translocated to the nucleus of infected cells and is 
capable of regulating the activity of nuclear factor κB (NF-κB) (de Los Santos et al. 2007). 
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2.7.2 STRUCTURE 
Both crystal and solution structures of Lbpro are available (Guarne et al. 1998, Cencic et 
al. 2007). The proteinase has been found to have a papain-like fold and is made up of a 
globular domain (Met29-Tyr183) from which a C-terminal extension (CTE) protrudes (Figure 
2-13). The globular domain is divided into two sub-domains. The N-terminal sub-domain is 
constructed of four α-helices and two very short antiparallel β-strands. The C-terminal sub-
domain consists of a mixed β-sheet that is composed of seven strands, two of them running 
parallel (β3-β4) whereas the rest is arranged antiparallel. The active site is found at the 
interface of the two sub-domains. The nucleophile (Cys51) is positioned at the top of helix α1. 
The general base His148 lies at the opposite site of the cleft together with Asp163 that 
positions His148 in the correct orientation. 
 
 
Figure 2-13 Crystal Structure of Lbpro as determined by Guarné et al. The proteinase is 
made up of an N-terminal, α-helical (green) and a C-terminal, β-sheet (magenta) sub-domain. The active 
site (Cys51, His148) is located at the top of the inter-domain cleft. Both forms of the CTE (ordered and 
unordered) are depicted (CTE1 and 2). 
Lbpro molecules were found to form dimers in the crystal structure. The CTE of one 
molecule can be found in the active site of the other molecule and vice versa. In all four dimers 
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in the asymmetric unit always one CTE is fully ordered whereas the other one contains 
unordered residues that could not be traced in the electron density map (Glu186-Glu191). 
Dimerization was also found in the solution structure of Lbpro (Cencic et al. 2007). Neither 
increasing the ionic strength (2M NaCl) nor decreasing protein concentration to 0.35mM was 
sufficient to tear the two molecules apart. These findings suggest that the quaternary 
structure of Lpro under physiological conditions may be a dimer, which would be in contrast to 
the idea of an intramolecular reaction during self-processing. However, Glaser et al. presented 
data which strongly argue for intramolecular self-processing. Further experiments will be 
needed to reveal the exact mechanism of Lpro. 
2.7.3 SUBSTRATE SPECIFICITY 
Lpro has developed a high degree of specificity, reflected by the fact that only three 
substrates of Lpro have been determined yet. These are the Lpro-VP4 junction of the polyprotein 
(Strebel and Beck 1986) and the two isoforms of eIF4G (Kirchweger et al. 1994, Gradi et al. 
2004). However, the cleavage sites found at these substrates vary strongly (Table 2-2). Lpro 
prefers lysine at P1 in the self processing reaction. The P1 lysine is found to point away from 
the substrate binding cleft and is sandwiched by Glu96 and Glu147 (Figure 2-14, green 
surfaces), enabling the formation of electrostatic interactions. Interestingly, glycine is found at 
P1 in the trans-cleavage sites in eIF4GI and II (Kirchweger et al. 1994, Gradi et al. 2004) 
although also lysine could be accepted in a trans-reaction by the leader protease (Kirchweger 
et al. 1994, Gradi et al. 2004). 
 
Table 2-2 Overview of the substrates known to be cleaved by Lpro. 
The requirements at position P2 were shown to be more stringent. The interactions 
between the P2 residue and the S2 binding pocket were found to be most important for 
substrate binding. Only leucine or valine are accepted at this position. This can be explained by 
Substrate P-region ? P’-region 
Lbpro-VP4 junction QRKLK  GAGQ 
eIF4G I FANLG  RTTL 
eIF4G II LLNVG  SRRS 
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39 Introduction 
2.8 AIMS 
Investigating protease substrate specificities plays an important role in the design of 
new protease inhibitors which have been shown to be promising agents for the development 
of anti-viral compounds. This thesis therefore analyzes substrate specificities of the two 
picornaviral proteinases 2Apro of HRV2 and HRV14 as well as Lbpro of FMDV. 
2Apro of HRV2 was shown to not accept the cleavage site found at the VP1-2Apro 
junction of HRV14 (Schertler 2008). Therefore, we set out to investigate which of the HRV14 
cleavage site residues are discriminated by HRV2 2Apro. Subsequently, residues of the substrate 
binding cleft that are responsible for this discrimination should be identified. Furthermore, we 
tried to determine why only glycine can be accepted at P1’ in the self-processing reaction 
while substrates with alanine at P1’ can be cleaved in trans by HRV2 2Apro. In another set of 
experiments, we intended to examine a hinge region at which the N-terminus is possibly 
rotated into the active site during self-processing. This mechanism has been proposed by 
Petersen et al. based on the structure of HRV2 2Apro (Petersen et al. 1999) but has not been 
confirmed by biochemical methods at present. 
Another aim was the construction of an active 2Apro hybrid consisting of the N-terminal 
domain of HRV14 and the C-terminal domain of HRV2. This hybrid proteinase was thought to 
help to understand differences between the 2A proteinases of HRV2 and HRV14 and to 
examine possible mechanistic differences. Finally, the influence of the protein 2B on 2Apro self-
processing should be investigated. 
Lbpro is not able to accept phenylalanine in the S2 pocket. Leu143 was shown to be 
responsible for this discrimination (Mayer et al. 2008). Leu143 is not completely conserved 
amongst all FMDV serotypes, as also methionine is found at position 143. Therefore, we set 
out to investigate whether methionine at position 143 executes the same function in 
discriminating between phenylalanine and leucine. 
  
  
3 MATERIAL & METHODS 
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3.1 PLASMIDS 
The wild type plasmids pCITE HRV2 VP1-2Apro and pCITE HRV14 VP1-2Apro were kindly 
provided by Carla Sousa; pCITE Lbpro-VP4-VP2 was obtained from Regina Cencic. The sequences 
coding for VP1-2Apro and Lbpro-VP4-VP2 are cloned into the plasmid pCITE (Novagen) 
downstream the internal ribosomal entry site (IRES) of the encephalomyocarditis virus (EMCV). 
pCITE HRV2 VP1-2Apro has been described (Glaser et al. 2003) and contains all but the 
first six basespairs of VP1 and the entire sequence coding for 2Apro followed by two stop 
codons. The sequence contains an MfeI site 29bp upstream the VP1-2Apro junction and a BstEII 
site 30bp downstream the junction which can be used for cassette cloning (Figure 3-1A). 
pCITE HRV14 VP1-2Apro contains the sequences for the entire VP1 and 2Apro also 
followed by two stop codons (Sousa et al. 2006). An AgeI site in VP1 and a SacII site in 2Apro 
have been introduced to enable proper cassette cloning (Figure 3-1B). 
For the construction of pCITE HRV2 VP1-2Apro-2B a 1610bp fragment was amplified 
from an HRV2 full length clone (fwd. Primer: TIM550; rev. Primer: TIM1637). The fragment 
contains VP1-2Apro-2B followed by two stop codons and a BamHI restriction site. An 
AgeI/BamHI fragment of the amplified product was then cloned into pCITE HRV2 VP1-2Apro 
(Figure 3-1C). 
pCITE HRV14 VP1-2Apro-2B was prepared in a similar way. A fragment containing 2Apro-
2B cDNA followed by two stop codons and a BamHI restriction site was amplified with the 
primers TIM1312 and TIM1650 from an HRV14 full length clone. The fragment and pCITE 
HRV14 VP1-2Apro were prepared by digestion with NsiI and BamHI and ligated to give the 
plasmid pCITE VP1-2Apro-2B (Figure 3-1D). 
The construction of the plasmid for an HRV14/2 hybrid 2Apro required introduction of 
an MfeI site into the plasmids pCITE HRV2 VP1-2Apro and pCITE HRV14 VP1-2Apro (TIM1618-
TIM1621). A 290bp MfeI/BamHI fragment of pCITE HRV2 VP1-2Apro was then used to exchange 
the corresponding fragment of pCITE HRV14 VP1-2Apro (Figure 3-1E) 
The plasmid pCITE Lbpro-VP4-VP2 has been described (Glaser et al. 2001). It contains 
nucleotides 892-1896 from FMDV O1k followed by two stop codons. The viral cDNA codes for 
the entire Lbpro including three additional N-terminal amino acids, all 85 amino acids of VP4 
and 78 amino acids of VP2. Cleavage sites can be modified by the exchange of a 38bp 
Bpu10I/SacI fragment in this plasmid (Figure 3-1F). 
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Figure 3-1 Schematic representations of the plasmids used in this thesis. Relevant 
restriction sites are listed. MfeI sites that are framed in (A) and (B) were introduced for the construction 
of the 2Apro hybrid (E) but are not present in the wild-type plasmid. 
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A T7 promoter precedes the CITE and enables the in vitro transcription of mRNA by T7 
RNA polymerase. The mRNAs contain the IRES in the 5’ UTR enabling proper initiation of 
translation. An ampicillin resistance gene allows screening for bacterial clones that carry the 
plasmid. 
3.2 OLIGONUCLEOTIDES 
All oligonucleotides were purchased from VBC-Biotech Service GmbH, Vienna. 
 
ID Length Sequence (5’→3’) Purpose 
TIM1536 52 
CCGGTAATTAAGAAGAGGAAAGGT
ATTATCACTACAGCTGGCCCGAGTC
CGC 
Introduction of the cleavage site 
IITTA*GPSP into pCITE HRV14/2 
VP1-2Apro. 
TIM1537 46 
GGACTCGGGCCAGCTGTAGTGATA
ATACCTTTCCTCTTCTTAATTA 
TIM1573 59 
AATTGTGACCAGACCAATTATCACT
ACAGCTGGCCTGGGCCCAATGTATG
TTCATGTAG Introduction of the cleavage site 
IITTA*GLGP into pCITE HRV2 VP1-
2Apro. 
TIM1574 60 
GTTACCTACATGAACATACATTGGG
CCCAGGCCAGCTGTAGTGATAATTG
GTCTGGTCAC 
TIM1590 59 
AATTGTGACCAGACCAATTATCAAA
TCATATGGCCCCAGTGACATGTATG
TTCATGTAG Introduction of the cleavage site 
IIKSY*GPSD into pCITE HRV2 VP1-
2Apro. 
TIM1591 60 
GTTACCTACATGAACATACATGTCA
CTGGGGCCATATGATTTGATAATTG
GTCTGGTCAC 
TIM1601 29 
GGGCCCCGGACCTAGGTATGGTGG
GGTAG Introduction of the cleavage site 
IITTA*GPGPRYGGVG into pCITE 
HRV2 VP1-2Apro. TIM1602 36 
GTTACCTACCCCACCATACCTAGGT
CCGGGGCCCGC 
TIM1603 29 
GGGCCCGAGTGACAGGTATGGTGG
GATTG Introduction of the cleavage site 
IITTA*GPSDRYGGI into pCITE HRV2 
VP1-2Apro. TIM1604 36 
GTTACCAATCCCACCATACCTGTCAC
TCGGGCCCGC 
TIM1605 29 
GGGCCCGAGTCCCATGTATGTTCAT
GTAG Introduction of the cleavage site 
IITTA*GPSP into pCITE HRV2 VP1-
2Apro. TIM1606 36 
GTTACCTACATGAACATACATGGGA
CTCGGGCCCGC 
TIM1642 29 
GGGCCCGAGTGACAGGTATGTTCA
TGTAG Introduction of the cleavage site 
IITTA*GPSDR into pCITE HRV2 VP1-
2Apro. TIM1643 36 
GTTACCTACATGAACATACCTGTCA
CTCGGGCCCGC 
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ID Length Sequence (5’→3’) Purpose 
TIM1644 29 
GGCCCCCAGTGACATGTACGTACAT
GTAG Introduction of the cleavage site 
IITTA*APSD into pCITE HRV2 VP1-
2Apro. TIM1645 36 
GTTACCTACATGTACGTACATGTCA
CTGGGGGCCGC 
TIM1646 29 
GGGCGCGAGTGACATGTACGTACA
TGTAG Introduction of the cleavage site 
IITTA*GASD into pCITE HRV2 VP1-
2Apro. TIM1647 36 
GTTACCTACATGTACGTACATGTCA
CTCGCGCCCGC 
TIM1648 59 
AATTGTGACCAGACCAATTATCAAA
TCATATGGCGCGAGTGACATGTACG
TACATGTAG Introduction of the cleavage site 
IIKSY*GASD into pCITE HRV2 VP1-
2Apro. 
TIM1649 60 
GTTACCTACATGTACGTACATGTCA
CTCGCGCCATATGATTTGATAATTG
GTCTGGTCAC 
TIM1659 59 
AATTGTGACCAGACCAATTATCACT
TCATATGGCCTGAGTGACATGTATG
TTCATGTAG Introduction of the cleavage site 
IITSY*GLSD into pCITE HRV2 VP1-
2Apro. 
TIM1660 60 
GTTACCTACATGAACATACATGTCA
CTCAGGCCATATGAAGTGATAATTG
GTCTGGTCAC 
Table 3-1 Oligonucleotides used for cassette-cloning. 
ID Length Sequence (5’→3’) Purpose 
TIM1599 21 ATCACTACCGCGGGCCCCAGT Introduction of a SacII restriction 
site into pCITE HRV2 VP1-2Apro. TIM1600 21 ACTGGGGCCCGCGGTAGTGAT 
TIM1607 27 
AAATCATATGGCTTAAGTGACATGT
AT Introduction of the mutation P2L 
(2Apro) into pCITE HRV2 VP1-2Apro 
IIKSY*GPSD. TIM1608 27 
ATACATGTCACTTAAGCCATATGAT
TT 
TIM1609 27 
TCATATGGCCCCGGGGACATGTATG
TT Introduction of the mutation S3G 
(2Apro) into pCITE HRV2 VP1-2Apro 
IIKSY*GPSD. TIM1610 27 
AACATACATGTCCCCGGGGCCATAT
GA 
TIM1611 27 
TATGGCCCCAGTCCAATGTATGTTC
AT Introduction of the mutation D4P 
(2Apro) into pCITE HRV2 VP1-2Apro 
IIKSY*GPSD. TIM1612 27 
ATGAACATACATTGGACTGGGGCC
ATA 
TIM1618 27 
ATACCACACTGCAATTGTACATCAG
GT Introduction of an MfeI restriction 
site into pCITE HRV14 VP1-2Apro. 
TIM1619 27 
ACCTGATGTACAATTGCAGTGTGGT
AT 
TIM1620 27 
CATTCCCTCTTGCAATTGTACCCAAG
C Introduction of an MfeI restriction 
site into pCITE HRV2 VP1-2Apro. 
TIM1621 27 
GCTTGGGTACAATTGCAAGAGGGA
ATG 
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ID Length Sequence (5’→3’) Purpose 
TIM1623 27 
GCTGGCATTTTCATGAAGGGGCAA
GAA Introduction of the mutation 
L143M (Lbpro) into pCITE Lbpro-VP4-
VP2. TIM1624 27 
TTCTTGCCCCTTCATGAAAATGCCA
GC 
TIM1627 36 
GGGGATCCAAGCCTATCATTGTCTT
TCATTGTAAGG 
Amplification of 2B including two 
stop codons and a BamHI 
restriction site from an HRV14 full 
length clone. Erroneous primer that 
gives rise to the mutation I94N in 
2B. 
Amplification of 2B including two 
stop codons and a BamHI 
restriction site from an HRV14 full 
length clone. 
TIM1650 39 
CCGGGGGATCCAAGCCTATCATTGT
CTTTCAATGTAAGG 
TIM1637 42 
AGCCCGGGGGATCCAAGCCTATCAT
TCTTTGTGTATATAATT 
Amplification of 2B including two 
stop codons and a BamHI 
restriction site from an HRV2 full 
length clone.  TIM550 18 GGACGTGGTTTTCCTTTG 
TIM1638 27 
AATGTTAAAATAAGGAATTACCACT
TG Introduction of the mutation M17R 
(2Apro) into pCITE HRV14 VP1-2Apro. 
TIM1639 27 
CAAGTGGTAATTCCTTATTTTAACAT
T 
TIM1640 27 
AACCTTATTTATATGAATCTTCATCT
T Introduction of the mutation R15M 
(2Apro) into pCITE HRV2 VP1-2Apro 
IIKSY*GLSD. TIM1641 27 
AAGATGAAGATTCATATAAATAAG
GTT 
TIM1651 27 
GACTGTGGTGGAATATTGCTATGCA
AA Introduction of the mutation K109I 
(2Apro) into pCITE HRV2 VP1-2Apro 
IITTA*GPSDR. TIM1652 27 
TTTGCATAGCAATATTCCACCACAG
TC 
TIM1653 27 
GACTGCGGTGGGAAGTTGAGATGC
ATA Introduction of the mutation I112K 
(2Apro) into pCITE HRV14 VP1-2Apro. 
TIM1654 27 
TATGCATCTCAACTTCCCACCGCAGT
C 
TIM1665 27 
AGAAATCTTCATGCTTTCAACTCTGA
G Introduction of the mutation L19A 
(2Apro) into pCITE HRV2 VP1-2Apro 
IITTA*APSD. TIM1666 27 
CTCAGAGTTGAAAGCATGAAGATTT
CT 
Table 3-2 Primers used for site directed mutagenesis via PCR. 
 
ID Length Sequence (5’→3’) Purpose 
TIM20 16 GCTAAACATGTCAAGG 
Forward sequencing primer for the 
HRV2 VP1-2Apro junction. 
TIM1334 18 ATACATCAAGGTTTAGTG 
Forward sequencing primer for the 
HRV14 VP1-2Apro junction. 
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ID Length Sequence (5’→3’) Purpose 
TIM550 18 GGACGTGGTTTTCCTTTG 
Forward sequencing primer for 
HRV2 and HRV14 VP1 and FMDV 
Lbpro. 
TIM554 18 ATTTAGGTGACACTATAG 
Reverse sequencing primer for 
HRV2 and HRV14 2Apro and FMDV 
VP2/VP4. 
Table 3-3 Primers used for sequencing. 
3.3 DNA METHODS 
3.3.1 AGAROSE GEL ELECTROPHORESIS 
Agarose gel electrophoresis was used throughout the cloning experiments to monitor 
the process. 1% agarose (Invitrogen) in 0.5x TAE-Buffer was used as a standard concentration. 
For the separation of smaller fragments, agarose concentration was raised up to 1.2%. An 
appropriate amount of 10x loading buffer was added to the samples before loading on the gel. 
1µg of HindIII digested λ-DNA was used as a size marker. Electrophoresis was carried out in 
0.5x TAE-Buffer at 80-110 Volts. Subsequently gels were soaked in ethidiumbromide solution 
for 15-30 minutes before being photographed on a UV trans-illuminator. 
 
0.5x TAE-Buffer:  20mM Tris base, 5mM Sodiumacetate, 1mM EDTA. 
10x Loading Buffer: 1mM EDTA, 0.1% Orange G, 10% Ficoll in 0.5x TAE-Buffer 
Ethidiumbromide: 10-4% Ethidiumbromide in 0.5x TAE-Buffer 
3.3.2 DNA RESTRICTION REACTIONS 
Analytical digestions were typically performed in a total volume of 20µl. Restriction 
enzymes and associated buffers were delivered by NewEngland BioLabs. Samples were mixed 
well and incubated at the appropriate temperature for 1-3 hours.  
x µl DNA 
2 µl NE Buffer (1-4) 
0.3 µl Enzyme 
y  µl H2O MILI Q 
20  µl 
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Vectors for ligations were prepared in a total volume of 100µl. The amount of enzyme 
varied from 0.5 to 1.0 µl. Again, the incubation was carried out at the adequate temperature 
for 2-14 hours. 
x  µl DNA 
10 µl NE Buffer (1-4) 
0.5-1.0 µl Enzyme 
y µl H2O MILI Q 
100  µl 
3.3.3 DEPHOSPHORYLATION OF DNA 5’ ENDS 
Dephosphorylation was preceded by phenol-chloroform extraction followed by 
precipitation with 3M sodium acetate and absolute ethanol. The dry pellet was resuspended in 
48.5µl H2O MILI Q and 1µl of calf intestine alkaline phosphatase (CIP) (NewEngland BioLabs, 
10u/µl) and 0.5µl 2M Tris-HCl (pH 8.0) were added. Samples were incubated at 37°C for 45 
minutes followed by another 45 minutes at 65°C.  
CIP is able to dephosphorylate the 5’ ends of DNA and prevents vectors from re-
ligation. Therefore, dephosphorylation is used to minimize the background in the cloning 
experiments. 
3.3.4 KINASING AND ANNEALING OF OLIGONUCLEOTIDES 
5’-phosphorylation of oligonucleotides was carried out using the enzyme T4 
polynucleotide kinase (PNK) (NewEngland BioLabs, 10u/µl). The enzyme catalyzes the transfer 
of the γ-phosphate of ATP to the 5’-OH of DNA, RNA or oligonucleotides to prepare an insert 
for ligation with a cloning vector. The reaction was carried out in a total volume of 20µl. 
2 µl 100mM ATP 
2 µl 10x PNK Buffer 
1 µl TIM XXXX (1µg/µl) 
1 µl TIM XXXX (1µg/µl) 
1 µl T4 PNK (NewEngland BioLabs, 10u/µl) 
13 µl H2O MILI Q 
20µl 
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A thermocycler with a temperature program of 37°C / 30min; 90°C / 30sec; 37°C / 
5min was used to incubate the samples and anneal the two oligonucleotides. Alternatively a 
program of 37° / 30min; 65°C / 10min; RT / 3hrs; 4°C / 4hrs was used. 
3.3.5 LIGATION OF DNA MOLECULES 
1µl of vector was loaded on an agarose gel to estimate the concentration of the DNA 
solution prior ligation. About 50ng of vector and 1µl of phosphorylation mix were incubated 
with 2µl 10x ligase buffer and 0.5µl T4-DNA-ligase (Promega, 3u/µl) in a total volume of 20µl at 
room temperature over night. Additional mixes with either no ligase or no insert served as 
negative controls. 
3.3.6 PHENOL-CHLOROFORM EXTRACTION 
In order to purify DNA, phenol-chloroform extraction followed by precipitation with 
sodium acetate and ethanol was used as a standard method. 3µl 0.5M EDTA (pH 8) per 100µl 
DNA solution were added followed by a 1x volume of phenol (containing 0.1% 8-
hydroxychinolin and equilibrated with 50mM Tris/HCl pH8). Samples were vortexed briefly and 
centrifuged for 1 minute at 13.000 rpm. The aqueous phase was transferred into a new tube 
and mixed with a 1x volume of chloroform. Vortexing, centrifuging and transfer of the aqueous 
phase was repeated as above. 
3.3.7 PRECIPITATION OF DNA 
Samples were mixed with 1/10 volume of 3M sodium acetate followed by 2 volumes of 
absolute ethanol. DNA was precipitated at -80°C for 15 minutes and centrifuged for 15 minutes 
at 14.000 rpm and 4°C. The supernatant was carefully removed and the pellet was dried on air 
for 30-60 minutes to remove any traces of ethanol. DNA was then redissolved in an 
appropriate volume of H2O MILI Q.  
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3.3.8 PURIFICATION BY COLUMN 
Alternatively, DNA was purified via an anion exchange mini column of the “Wizard® SV 
Gel and PCR Clean up System” by Promega. DNA was eluted from the column with an 
adequate volume of H2O MILI Q. 
3.3.9 EXTRACTION OF DNA FROM AGAROSE GELS 
Bands were cut out under UV light and DNA was isolated from the gel by the use of the 
“Wizard® SV Gel and PCR Clean up System” by Promega. DNA was eluted from the column with 
an appropriate amount of H2O MILI Q. 
3.3.10 INTRODUCTION OF MUTATIONS BY STANDARD PCR TECHNIQUES 
PCR with mutated primers was used to introduce mutations of one to a few basepairs. 
Complementary primers that carry the mutated site were designed and used in a PCR reaction 
with a proofreading polymerase. The 9-12 basepairs long regions flanking the mutated site 
allow proper hybridization of the primer with the template and therefore introduction of the 
mutation. The PCR product is then transformed into TOP 10F’ cells which fix the gaps and 
create regular plasmids. A standard mix for this method contained: 
0.5 µl Template DNA 
1 µl Primer fwd (1µg/µl) 
1 µl Primer rev (1µg/µl) 
4 µl dNTP’s (2.5mM) (GE Healthcare) 
5 µl 10x Pfu Buffer (Promega) 
1 µl Pfu Polymerase (Promega, 3u/µl)  
38.5 µl H2O MILI Q 
50 µl 
 
Mixes lacking primers were used as a negative control. PCR was performed on a Perkin 
Elmer DNA Thermal Cycler 480 with a temperature program of: 
95°C    2min     
95°C    30sec   
annealing Temperature  1min   30x 
68°C    10min     
4°C    ∞ 
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Annealing temperature was originally chosen 5-10°C below the calculated melting 
temperature of the primers and was adjusted in case of an unsatisfactory product. 10µl of the 
PCR mix were loaded on an agarose gel to check the quality of the product. The remaining 40µl 
were mixed with 4.5µl NE-Buffer 4 and 1µl of DpnI and incubated at 37°C for 5 hours. DpnI 
requires methylation of the adenines in its recognition sequence allowing specific digestion of 
the template DNA. 10µl of this mix were then transformed into TOP 10F’ cells (see 3.4.2). 
3.3.11 MANIPULATION OF CLEAVAGE SITES BY CASSETTE CLONING 
Cassette cloning was chosen as the standard mutagenesis method to introduce a 
number of mutations at once. Oligonucleotides were delivered by VBC biotech (see 3.2). Two 
complementary oligonucleotides were 5’-phosphorylated and annealed (see 3.3.4) to form an 
insert with the correct sticky ends. Vectors were created by digestion with the appropriate 
restriction enzymes (see 3.3.2), dephosphorylated (see 3.3.3) and purified by gel extraction 
(see 3.3.9). Vector and insert were then ligated (see 3.3.5) and transformed into E. coli (strain 
TOP 10F’) (see 3.4.2). 
3.4 BACTERIAL CULTURES 
3.4.1 PREPARATION OF COMPETENT CELLS 
Both the TOP 10F’ strain as well as the DH5α strain of E. coli were used for cloning 
experiments. Cells were made competent by using the CaCl2 method. A starter culture was set 
up by inoculation of 3ml LB-Medium and shaking at 37°C over night. On the following day, 
200ml LB-Medium were inoculated with the starter culture and grown at 37°C for 2-4 hours 
until an optical density of 0.4-0.5 was reached. Harvesting of cells was carried out by 
centrifugation in sterile Falcon-tubes at 5.000 rpm for 5 min in a swinging bucket (4°C). After 
harvesting, cells were constantly kept at 4°C. The bacterial pellet was resuspended in 25ml ice-
cold 0.1M CaCl2 solution and incubated on ice for 25min. Centrifugation was repeated, the 
pellet again resuspended in 10ml 0.1M CaCl2 solution and incubated at 4°C over night. The 
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next day, the suspension was mixed gently with 2ml sterile glycerol, portioned into 200µl 
aliquots and frozen in liquid nitrogen. Competent cells were stored at -80°C. 
 
LB-Medium:  1% Bacto-Trypton, 0.5% Yeast-Extract, 10mM Tris/HCl pH 7.5, 170mM NaCl 
LB-Amp-Medium: contains 100mg/L Ampicillin 
3.4.2 TRANSFORMATION 
E. coli of the strains TOP 10F’ and DH5α were used for transformation in the cloning 
experiments. A 200µl aliquot of competent cells per transformation was thawed and kept on 
ice for 10 minutes. Addition of 10µl ligation or PCR mutagenesis mix was followed by 
incubation for 15 minutes on ice. Samples were then heat shocked at 42°C for 30-60 seconds, 
transferred on ice again and mixed with 400µl preheated (37°C) LB-medium. After incubation 
at 37°C for 20-30 minutes, 150µl were plated on LB-Amp Agar-Agar plates. The remaining 
bacteria was spinned down at 8.000 rpm for 20 seconds followed by the removal of all but 
about 100µl medium. Bacteria were resuspended in the remaining medium and plated on a 
separate LB-Amp Agar-Agar plate. Plates were incubated at 37°C over night to allow bacteria 
to form colonies. 
 
LB-Amp Agar-Agar plates: Add 1.5% Agar-Agar to LB-Medium. Autoclave at 120°C for 20 
minutes. Let cool down, add ampicillin (100mg/L) and pour plates. 
3.4.3 DNA MINI PREPS 
Small scale DNA preparations (MINI preps) from transformed E. coli were used to 
screen for positive mutants by digesting DNA with restriction enzymes. MINI preps purified by 
phenol-chloroform extraction or anion exchanger mini columns were also used for DNA-
sequencing. 
Colonies were picked from LB-Amp plates to inoculate 4ml of LB-Amp medium. 
Samples were incubated at 37°C over night in a bacterial shaker. On the next day cells were 
harvested in 1.5ml tubes by spinning down the solution at 6.000 rpm for 2 minutes and 
discarding the supernatant twice. The pellet was resuspended in 100µl Solution I and mixed 
gently with 200µl Solution II. After addition of 150µl Solution III, samples were again mixed 
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gently and centrifuged for 5 minutes at 14.000 rpm and 4°C. The supernatant was transferred 
to a new tube and DNA was precipitated by the addition of 1ml ice-cold absolute ethanol. 
Centrifugation was repeated as above and the supernatant was discarded. The DNA pellet that 
contains salt and RNA was then taken up in 200µl TE-Buffer. 200µl 5M LiCl were added 
followed by a step of centrifugation as above. Again, the supernatant was transferred to a new 
tube. DNA was once more precipitated with 1ml ice-cold absolute ethanol and collected by a 
final centrifugation as above. The supernatant was discarded and the pellet was dried on air 
for about 1 hour. Subsequently DNA was taken up in 50µl H2O MILI Q and stored at -20°C. 
 
Sol I:  50mM Tris/HCl pH 8.0, 10mM EDTA, 100µg/ml RNaseA 
Sol II:  20mM NaOH, 1% SDS 
Sol III:  2.8M Potassiumacetate pH 5.1 
TE-Buffer: 10mM Tris/HCl pH 8.0, 1mM EDTA 
3.4.4 DNA MIDI PREPS 
Middle scale DNA preparations (MIDI preps) were used for preparation of larger 
amounts of very clean DNA for in vitro transcription. Both, the “Plasmid DNA Purification Kit” 
(Macherey-Nagel) and the “E.Z.N.A.® Plasmid Midi Prep Kit” (OMEGA BIO TEK) were used 
following the instructions of the respective company. DNA was resuspended in 200µl H2O MILI 
Q and stored at -20°C. 
3.5 RNA METHODS 
3.5.1 IN VITRO TRANSCRIPTION 
In all HRV plasmids the two stop codons at the end of 2Apro are followed by a BamHI 
restriction site. 20µl of plasmid from a MIDI prep were linearized at this site to avoid 
unnecessary long transcripts. In case of pCITE Lbpro-VP4-VP2 this digestion was performed with 
SalI. After checking the linearization on an agarose gel, DNA was purified via phenol-
chloroform extraction and precipitated with 3M sodium acetate and absolute ethanol. The air 
dried pellet was resuspended in 
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20 µl 5x Transcription buffer (Promega) 
5 µl 100mM DTT (Promega) 
10 µl 2.5mM NTP mix (GE Healthcare) 
3 µl RNasin (Promega, 40u/µl) 
1 µl T7 RNA polymerase (Promega, 20u/µl) 
61 µl H2O MILI Q 
100µl 
 
and incubated at 37°C for 90 minutes. Subsequently 0.6µl DNAse I (Invitrogen, 512u/µl) were 
added followed by another 20 minutes of incubation at 37°C to digest the template DNA. The 
resulting RNA was purified via phenol-chloroform extraction (see 3.3.6) followed by 
precipitation with ammoniumacetate and absolute ethanol (see 3.5.2). 
3.5.2 PRECIPITATION OF RNA 
For precipitation, a 1/3 volume of 8M ammonium acetate and 2.5 volumes of absolute 
ethanol were added to the purified RNA and incubated at -80°C for 15 minutes. The RNA was 
then centrifuged for 15 minutes at 14.000 rpm and 4°C. The supernatant was discarded and 
the RNA pellet was washed with 500µl 70% ethanol. Centrifugation and discarding was 
repeated as above and the pellet was dried on air for about 1 hour. Subsequently, RNA was 
resuspended in 25µl H2O MILI Q. 
3.5.3 RNA AGAROSE GEL ELECTROPHORESIS 
After in vitro transcription, 2µl of RNA were checked on a 1% agarose 0.1% SDS gel. 
Gels were washed in deionized water for 30 minutes before staining in 0.5x TAE-Buffer 
containing ethidiumbromide for 15-30 minutes. Subsequently, bands were visualized on a UV 
trans-illuminator. 
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3.6 PROTEIN METHODS 
3.6.1 IN VITRO TRANSLATION 
The ability of the viral proteases to perform self-processing was assayed by a time 
course in vitro translation. Rabbit reticulocyte lysate (RRL) was programmed with an in vitro 
transcribed mRNA coding for VP1-2Apro, VP1-2Apro-2B or Lbpro-VP4-VP2 respectively. Aliquots of 
the newly synthesized viral proteins were taken at determined times, separated via SDS-PAGE 
and made visible by fluorography. To estimate the best amount of RNA for in vitro translation, 
a pilot reaction was performed. 
3.6.1.1 PILOT REACTION 
In vitro transcribed RNA was diluted 2:10, 3:10 and 4:10 to assay the best 
concentration for the time course experiment. For each dilution as well as for a negative 
control the following mix was prepared: 
7 µl RRL (Promega) 
0.2 µl 1mM amino acids mix without methionine (Promega) 
0.2 µl RNasin (Promega, 40u/µl) 
0.4 µl 10µM 35S methionine (1000Ci/mmol) (Hartmann Analytics) 
1.2 µl H2O MILI Q 
9 µl 
 
The mix was preheated to 30°C for 2 min before 1µl of each RNA dilution and 1µl H2O 
for the negative control was added. Samples were incubated at 30°C for 20 min. Subsequently, 
1µl ice-cold unlabeled methionine/cysteine mix (20mM) was added and the samples were 
placed on ice immediately to stop the translation. Samples were mixed with 25µl 2x Laemmli 
sample buffer and 15µl H2O before being loaded on a 17.5% SDS-polyacrylamide gel (see 
section 3.6.2). After SDS-PAGE, gels were dried and the newly synthesized protein bands were 
visualized by fluorography (see 3.6.3). 
 
2x Laemmli sample buffer: 20% Glycerol, 10% β-Mercaptoethanol, 6% SDS, 125mM Tris, 0.01% 
Bromophenol Blue, pH 6.8 
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3.6.1.2 TIME COURSE TRANSLATION 
The results of the pilot reaction helped to decide on the best RNA concentration. In 
order to examine the cis cleavage of 2Apro and Lbpro over time, a time course translation was 
set up. It contained the time points of 0min, 10min, 20min, 30min, 60min, 120min, 180min 
and 300min for 2Apro. In case of the leader protease the time points of 0min, 4min, 8min, 
12min, 20min, 30min and 60min were chosen. Therefore, a x-times mastermix of the above 
translation mix was produced. 9µl of the mastermix were transferred into a new tube and 
served as a negative control. Samples were preheated to 30°C for 2 min before (x-1) µl of RNA 
and 1µl of water respectively were added to the tubes. Samples were incubated at 30°C. 
Aliquots of 10µl were taken at the given time points and put on an ice-cold mix of 1µl 
unlabeled methionine/cysteine (20mM), 25µl 2x Laemmli sample buffer and 15µl H2O to stop 
the reaction. SDS-PAGE and fluorography served again as methods to visualize the newly 
synthesized viral proteins. 
3.6.2 SDS POLYACRYLAMIDE GEL ELECTROPHORESIS 
The SDS-polyacrylamide gelelectrophoresis system of Dasso & Jackson (Dasso and 
Jackson 1989) was used to analyze the translation products. This discontinuous system is made 
up of two gel-parts which differ in pH and are buffered with Tris-glycine. The 0.75mm thick 
gels were made up of a separating gel (pH 8.8) that contained 17.5% acrylamide covered by a 
5% stacking gel (pH 6.8). Samples were heated to 95°C for 5 min before 10µl were loaded to 
the gel. Gels were run in 1x running buffer (Biorad PAGE system) at 10mA for the stacking gel 
and 15mA for the separation gel. 14C labeled CFA.626 (Amersham) was used as size marker. 
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Stacking Gel  Seperation Gel 
3.5 ml 30% Acrylamide  0.333 ml 30% Acrylamide 
0.158 ml 2.5% Bisacrylamide  0.104 ml 2.5% Bisacrylamide 
1.5 ml 4x Lower Gel Buffer  0.5 ml 4x Lower Gel Buffer 
0.809 ml H2O  1.06 ml H2O 
0.03 ml 10% Ammoniumpersulphate  0.02 ml 10% Ammoniumpersulphate 
0.003 ml TEMED  0.002 ml TEMED 
Table 3-4 Composition of SDS-Polyacrylamide gels. 
4x Lower Gel Buffer:  1.5M Tris/HCl pH 8.8, 0.4% SDS 
4x Upper Gel Buffer:  0.5M Tris/HCl pH 6.8, 0.4% SDS 
10x Running Buffer:  500mM Tris, 3.85M Glycine, 1% SDS 
3.6.3 FLUOROGRAPHY 
Fluorography was used to visualize the newly synthesized and 35S labeled proteins. 
Therefore, the gels were soaked 2x 15min in 100ml enhancing buffer, dried on a gel drier and 
exposed to a KODAK BioMax MR film for 20-90 hours. Films were developed on an AGFA 
Curix60. 
 
Enhancing Buffer:  1M Sodiumsalycilate, 45% Methanol 
4 RESULTS 
   
 
61 Results 
An in vitro system was used to investigate the cis-cleavage of the viral proteases on 
different cleavage sites. The viral genes of interest were cloned downstream of the EMCV IRES 
of the plasmid pCITE. The restriction sites MfeI and BstEII as well as AgeI and SacII respectively 
were used to modify the cleavage sites at the HRV2 and HRV14 VP1-2Apro junctions by cassette 
cloning. In the plasmid pCITE Lbpro-VP4-VP2 the cleavage site was modified by exchanging a 
Bpu10I/SacI fragment (see section 1.1). Mutations at positions lying apart of these cassettes 
were introduced by the use of standard PCR-techniques (see section 3.3.10). Plasmids were 
linearized by BamHI or SalI digestion prior in vitro transcription from the T7-start (see section 
3.5.1). The mRNA obtained was then used for in vitro translation in RRL’s. Proteins were 
labeled by the use of 35S-Met. Aliquots were taken at specific time points of the reaction (see 
section 3.6.1). Proteins were then separated by SDS-PAGE and visualized by fluorography (see 
sections 3.6.2 and 3.6.3) 
4.1 CLEAVAGE OF WILD-TYPE SUBSTRATES BY HRV2 AND HRV14 
2APRO 
 
Figure 4-1 Self-processing of (A) HRV2 and (B) HRV14 2Apro on the respective wild-type 
cleavage sites. Rabbit reticulocyte lysate was programmed with RNA coding for VP1-2Apro (10ng/µl) and 
incubated at 30°C. Negative controls were prepared by adding water instead of RNA. 10µl aliquots were 
taken at the given time points and put on an icecold mix of 25µl 2x Laemmli sample buffer, 15µl H20 and 
1µl unlabeled methionine/cysteine (20mM). Viral proteins were then separated by SDS-PAGE on 17.5% 
gels and visualized by fluorography. Protein standards (M) in kDa are given on the left. 
The kinetics of cis-cleavage by wild-type HRV2 and HRV14 2Apro on their respective 
wild-type cleavage sites are very similar. For HRV2 2Apro, the first cleavage products could be 
detected after 20 minutes and 50% of the precursor was cleaved after about 30 minutes 
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(Figure 4-1A). HRV14 2Apro performs this cis reaction slightly slower (Figure 4-1B). The first 
cleavage products were not detected before 30 minutes after start of translation and 50% of 
conversion was reached between 30 and 60 minutes. HRV2 2Apro could not be detected due to 
low sensitivity. In HRV2, VP1 contains seven methionine residues whereas 2Apro only contains 
two. 2Apro of HRV14 is generally easier to detect as it contains three methionine residues and 
only five methionines are found in VP1. 
4.2 HRV2 2APRO CANNOT ACCEPT THE VP1-2APRO CLEAVAGE SITE 
OF HRV14 
Recently, it has been shown that HRV2 2Apro is not able to accept the cleavage site of 
HRV14 (AspIleLysSerTyr*GlyLeuGlyPro) at the VP1-2Apro junction in cis (Schertler 2008). In our 
first experiment we were able to reproduce this finding (Figure 4-2A). No cleavage products 
could be detected, even at 300 minutes after start of translation. We set out to investigate 
which of these residues were responsible for this discrimination. Therefore, a number of HRV2 
VP1-2Apro mutants with different combinations of cleavage sites was produced and tested for 
their ability to perform self-processing. Finally, residue 15 in HRV2 2Apro and residue 17 in 
HRV14 2Apro located in a putative S2’ pocket were mutated to investigate their influence in 
recognizing the residue at P2’. Table 4-1 gives an outline of all mutants described in this 
section. Each of them will be discussed in detail below. 
 
Serotype VP1 ? 2Apro Additional mutations Figure 
HRV2 DIKSY  GLGP  Figure 4-2A 
HRV2 IITTA  GPSP  Figure 4-2B 
HRV2 IITTA  GLGP  Figure 4-2C 
HRV2 IIKSY  GPSD  Figure 4-2D 
HRV2 IIKSY  GPSP  Figure 4-3A 
HRV2 IIKSY  GPGD  Figure 4-3B 
HRV2 IIKSY  GLSD  Figure 4-3C 
HRV2 IITSY  GLSD  Figure 4-3D 
HRV2 IIKSY  GLSD 2Apro: R15M Figure 4-5A 
HRV14 DIKSY  GLGP 2Apro: M17R Figure 4-5B 
Table 4-1 Overview of the HRV2 and HRV14 VP1-2Apro mutants described in section 4.2. 
Residues at the VP1-2Apro junction are listed. Underlined residues in the HRV2 mutants differ from the 
wild-type sequence and are found at equivalent positions at the HRV14 VP1-2Apro junction. Time course 
translations of each mutant can be found in the figures listed on the right. 
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A major difference between the P’ regions of HRV2 and HRV14 is the presence of the 
negatively charged residue aspartic acid at P4’ in HRV2 and the hydrophobic amino acid 
proline at P4’ in HRV14. Therefore, we wanted to investigate if the single mutation D4P in 
HRV2 2Apro would stop the protease from processing this cleavage site. Figure 4-2B shows the 
result for this experiment. Very similar to the processing of the wild-type cleavage site, the first 
cleavage products were detected after 20 minutes (compare Figure 4-1A). 30 minutes after the 
start of translation, 50% of the VP1-2Apro precursor was cleaved and the reaction was 
completed between 60 and 120 minutes. 
 
 
Figure 4-2 Self-processing of HRV2 2Apro on cleavage sites containing residues found at 
the junction of HRV14 VP1-2Apro: (A) entire cleavage site found in HRV14. (B)-(D) mixed cleavage sites. 
Underlined residues differ from the residues found in the wild-type cleavage site. Rabbit reticulocyte 
lysate was programmed with RNA coding for VP1-2Apro (10ng/µl) and incubated at 30°C. Negative 
controls were prepared by adding water instead of RNA. 10µl aliquots were taken at the given time 
points and put on an icecold mix of 25µl 2x Laemmli sample buffer, 15µl H20 and 1µl unlabeled 
methionine/cysteine (20mM). Viral proteins were then separated by SDS-PAGE on 17.5% gels and 
visualized by fluorography. Protein standards (M) in kDa are given on the left. 
The single mutation D4P was not sufficient to prevent HRV2 2Apro from cleaving at this 
site. Thus, further mutations in the P’ region were thought to be necessary to affect self-
processing. Introduction of three residues from HRV14 into the HRV2 VP1-2Apro cleavage site 
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(LeuGlyPro instead of ProSerAsp at P2’-P4’) resulted in a slight delay in self-processing (Figure 
4-2C). Nevertheless, the time point of 50% conversion was only shifted to a minor degree and 
was found between 30 and 60 minutes, indicating that the changes in the P’ region are not 
responsible for the discrimination of the HRV14 cleavage site by HRV2 2Apro. For this reason, 
we wanted to investigate the influence of the region P3-P1 on self-processing by mutating the 
residues ThrThrAla to LysSerTyr that are found in the VP1-2Apro cleavage site of HRV14. 
Surprisingly, the kinetics of cleavage were again only slightly slowed (Figure 4-2D). The first 
cleavage products could not be detected before 30 minutes and 50% of the precursor were 
cleaved at about 60 minutes. Nevertheless, all of the mutated cleavage sites so far 
investigated, were clearly processed by HRV2 2Apro indicating that mutations upstream as well 
as downstream of the cleavable bond are necessary to stop HRV2 2Apro from processing this 
cleavage site in cis. 
 
 
Figure 4-3 Self-processing of HRV2 2Apro on cleavage sites containing residues found at 
the junction of HRV14 VP1-2Apro. Underlined residues differ from the residues found in the wild-type 
cleavage site. Rabbit reticulocyte lysate was programmed with RNA coding for VP1-2Apro (10ng/µl) and 
incubated at 30°C. Negative controls were prepared by adding water instead of RNA. 10µl aliquots were 
taken at the given time points and put on an icecold mix of 25µl 2x Laemmli sample buffer, 15µl H20 and 
1µl unlabeled methionine/cysteine (20mM). Viral proteins were then separated by SDS-PAGE on 17.5% 
gels and visualized by fluorography. Protein standards (M) in kDa are given on the left. 
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As the mutant with LysSerTyr at P3-P1 was the most severely affected, we decided to 
keep these mutations and introduce additional single mutations in the region P2’-P4’. Figure 
4-3A shows the influence of the additional mutation aspartic acid to proline at P4’. HRV2 2Apro 
was still able to process this cleavage site, albeit at a much lower rate than the wild-type 
cleavage site. Initial cleavage products could still be detected after 20 minutes. Nevertheless, 
50% conversion of the precursor was not found until 120 minutes after start of translation, 
supporting the theory that mutations at both sides of the cleavable bond are necessary to stop 
HRV2 2Apro from self-processing. Introduction of glycine instead of serine at P3’ caused an even 
greater impairment of self-processing activity (Figure 4-3B). Although some cleavage product 
could still be detected after 20 to 30 minutes, a clear time point of 50% cleavage could not be 
detected any longer. Whether the detected cleavage product is still the result of specific 
cleavage by 2Apro remains doubtful. 
Finally, introduction of leucine at P2’ in the background of LysSerTyr at P3-P1 results in 
a pattern comparable to the one found with the entire HRV14 cleavage site (Figure 4-3C). Only 
a very low amount of non-precursor protein could be detected indicating that HRV2 2Apro was 
no longer able to process this cleavage site. Therefore, these four mutations prevent HRV2 
2Apro from self-processing. However, the minimal number of HRV14 residues that are sufficient 
to impair HRV2 2Apro self-processing remains to be shown. Thus, we reintroduced the wild-
type residue threonine at P3 and tested if the remaining HRV14 residues were still sufficient to 
prevent cleavage. Figure 4-3D shows that this mutant resulted in a pattern that was more 
comparable to the one found with the cleavage site IleIleLysSerTyr*GlyProGlyAsp (compare 
Figure 4-3B). 
These results strongly argue against our previous assumptions that the region P2’-P4’ 
is not involved in the discrimination of the HRV14 cleavage site. Comparison of Figure 4-2D 
with Figure 4-3C shows that introduction of leucine at P2’ in the background of LysSerTyr at 
P3-P1 severely impairs self-processing. Therefore, we wanted to investigate residues that are 
involved in the recognition of the P2’ proline. Unfortunately, no structure of a 2Apro with its 
substrate bound to the active site is available. The crystal structure of HRV2 2Apro represents a 
picture of the protease after self-processing has taken place. The N-terminus is rotated out of 
the active site. Thus, the P2’ proline is placed a long way off from its position during self-
processing. Nevertheless, investigation of this crystal structure revealed a putative binding 
pocket for the proline at P2’ (Figure 4-4A). It is made up of Arg15, Leu19, Phe20, Tyr39 and the 
main chain atoms of Asn16. Sequence alignments of several HRV serotypes showed that Arg15 
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is conserved among group A viruses whereas a conserved methionine is found at the 
equivalent position in group B viruses (Met17) (Figure 4-4B). This finding let us hypothesize 
that Arg15 may be involved in discriminating proline from this pocket although the relatively 
large distance from Arg15 from the active site (8.9 Å between the Cα atoms of Cys106 an 
Arg15) argued against this. 
 
 
Figure 4-4 (A) Putative binding pocket for the P2’ proline in HRV2 2Apro. Residues forming 
the pocket are shown in purple. The P2’ proline is depicted in red and the active site cysteine (Cys106) is 
colored yellow (generated with the “protein movie generator” (Autin and Tuffery 2007)). (B) Partial 
multiple sequence alignment of several HRV 2Apro sequences. The position of R15 and M17 respectively 
is highlighted in purple. Blocks of Group A and Group B viruses are separated by a blue line (generated 
with JalView (Clamp et al. 2004)). 
We therefore introduced the mutation R15M into the plasmid pHRV2 VP1-2Apro 
IleIleLysSerTyr*GlyLeuSerAsp and tested whether this was sufficient to compensate the effect 
of leucine at P2’. Figure 4-5A shows that self-processing could not be restored (compare Figure 
4-3C), indicating that Arg15 is not involved in discriminating leucine from the P2’ position. 
Nevertheless, in a reverse experiment, we tested for self-processing of a HRV14 2Apro M17R 
mutant. Figure 4-5B shows that this mutant was unable to perform self-processing on the wild-
type HRV14 cleavage site. This finding and the fact that position 15 (HRV2) and position 17 
(HRV14) respectively are conserved within the two genetic groups suggests that this residue 
has some important function, albeit not in the recognition of the P2’ residue. 
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Figure 4-5 Self-processing of HRV2 and HRV14 2Apro mutants. (A) Effect of the mutation 
R15M in HRV2 2Apro on the self-processing of the sequence IleIleLysSerTyr*GlyLeuSerAsp. Underlined 
residues differ from the residues found in the wild-type cleavage site. (B) Effect of the mutation M17R in 
HRV14 2Apro on the self-processing on its wild-type cleavage site. Rabbit reticulocyte lysate was 
programmed with RNA coding for VP1-2Apro (10ng/µl) and incubated at 30°C. Negative controls were 
prepared by adding water instead of RNA. 10µl aliquots were taken at the given time points and put on 
an icecold mix of 25µl 2x Laemmli sample buffer, 15µl H20 and 1µl unlabeled methionine/cysteine 
(20mM). Viral proteins were then separated by SDS-PAGE on 17.5% gels and visualized by fluorography. 
Protein standards (M) in kDa are given on the left. 
4.3 NUP62 CONTAINS SEQUENCES THAT WERE FOUND TO BE 
CLEAVED IN TRANS BUT CANNOT BE ACCEPTED IN CIS BY 
HRV2 2APRO 
It has been shown that proteins of the nuclear pore complex (NUPs) are targets of 
2Apro in trans-cleavages (Gustin and Sarnow 2001, Park et al. 2008). Moreover, recent studies 
revealed that HRV2 2Apro is able to directly cleave Nup62 at multiple sites (Park N. and Gustin 
K., pers. comm.). The cleavage sites used by HRV2 2Apro were identified by N-terminal 
sequencing and sequence analysis and are listed in Table 4-2. Alanine residues were found to 
be present at both the P1’ and P2’ position in these cleavage sites. Thus, we were interested 
whether HRV2 2Apro was also able to cleave substrates containing alanine either at P1’ or P2’ in 
cis. In agreement with our previous results that a mutation in the region P2’-P4’ without 
additional mutations in the P3-P1 region did not significantly disturb self-processing, HRV2 
2Apro was able to process a cleavage site with the single mutation proline to alanine at P2’ at 
wild-type levels. First cleavage products could be detected at 20 minutes and 50% of the 
precursor were cleaved at about 30 minutes (Figure 4-6A, compare Figure 4-1A). As we knew 
that mutating proline at P2’ in the background of LysSerTyr at P3-P1 had dramatic effects on 
self processing, we were interested how such a mutant with alanine at P2’ would compare to 
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the mutant with leucine at P2’. Figure 4-6B shows that also alanine cannot be accepted in the 
background of the three mutated residues at P3-P1 (compare Figure 4-3C). 
 
Table 4-2 Comparison of the HRV2 2Apro self-processing cleavage site with cleavage sites 
found in the trans-cleavage of Nup62. ND=not detected, cp=cleavage product. 
 
 
Figure 4-6 Self-processing of HRV2 2Apro and a 2Apro L19A variant on cleavage sites 
containing alanine at either P1’ or P2’. Underlined residues differ from the residues found in the wild-
type cleavage site. Rabbit reticulocyte lysate was programmed with RNA coding for VP1-2Apro (10ng/µl) 
and incubated at 30°C. Negative controls were prepared by adding water instead of RNA. 10µl aliquots 
were taken at the given time points and put on an icecold mix of 25µl 2x Laemmli sample buffer, 15µl 
H20 and 1µl unlabeled methionine/cysteine (20mM). Viral proteins were then separated by SDS-PAGE 
on 17.5% gels and visualized by fluorography. Protein standards (M) in kDa are given on the left. 
Cleavage site  P4 P3 P2 P1 ? P1‘ P2‘ P3‘ P4‘ 
Self-processing  I T T A  G P S D 
Nup62 ND/cp5  V T T A  G A P T 
Nup62 ND/cp6  A T T A  G A T Q 
Nup62 ND/cp3  L K P L  A P A G 
Nup62 cp8/cp1  L S N T  A A T P 
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Glycine at P1’ is the only totally conserved residue found at the VP1-2Apro junction of 
all HRV serotypes sequenced so far. Indeed, peptides with glutamic acid, lysine, threonine, 
phenylalanine or aspartic acid at P1’ were shown to remain uncleaved by HRV2 2Apro (Skern et 
al. 1991, Sommergruber et al. 1992), confirming this strong requirement for glycine at P1’. 
Nevertheless, we tested the ability of HRV2 2Apro to accept a cleavage site containing alanine 
at P1’. Figure 4-6C shows that the single addition of a methyl group at this position results in 
total disruption of self-processing, indicating that glycine is really the only residue that can be 
accepted at P1’ in the self-processing reaction. Petersen et al. suggested that Leu19 is 
responsible for discriminating any other residue from P1’ by blocking any access to a possible 
S1’ site (Petersen et al. 1999) (Figure 4-4A). Nevertheless, mutating Leu19 to alanine in order 
to provide more space for alanine at P1’ did not significantly enhance self-processing (Figure 
4-6D), suggesting that the occupancy of space by Leu19 is not the only reason for the strong 
requirement for glycine at P1’. 
4.4 MET5: A HINGE AT WHICH THE N-TERMINUS IS ROTATED INTO 
THE ACTIVE SITE DURING SELF-PROCESSING? 
Skern et al. have shown that a peptide with the sequence IVTRPIITTA*GPGPRYGGVG 
(underlined residues are the ones found in the equivalent positions of the HRV14 VP1-2Apro 
junction) is not cleaved by HRV2 2Apro (Skern et al. 1991). In order to test this cleavage site in 
the cis reaction we introduced it into the VP1-2Apro junction of our in vitro system and tested 
for self-processing. Figure 4-7A shows that the cleavage site could not be processed by HRV2 
2Apro in cis, just as in trans. In order to exclude the possible influence of the altered P3’ and P4’ 
positions we introduced the cleavage site IITTA*GPSDRYGGI. Again we tested for self-
processing and found that this cleavage site was not recognized by HRV2 2Apro (Figure 4-7B). 
Comparison of the HRV2 and HRV14 cleavage site revealed that the mutation of the 
hydrophobic residue methionine to the charged amino acid arginine at position P5’ is one of 
the major differences and could cause the inability of HRV2 2Apro to process these cleavage 
sites. 
The crystal structure of HRV2 2Apro gives a picture of the protease after the cis cleavage 
event, where the N-terminus is turned away from the active site. Petersen et al. proposed that 
any rearrangement beyond Met5 would probably alter the interactions within the N-terminal 
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β-sheet (Petersen et al. 1999). Thus, rearrangements of the first five residues must be 
sufficient to place the scissile bond in the active site (Figure 4-8). 
 
 
Figure 4-7 Self-processing of HRV2 2Apro on substrates containing arginine at P5’. 
Underlined residues differ from the residues found in the wild-type cleavage site. Rabbit reticulocyte 
lysate was programmed with RNA coding for VP1-2Apro (10ng/µl) and incubated at 30°C. Negative 
controls were prepared by adding water instead of RNA. 10µl aliquots were taken at the given time 
points and put on an icecold mix of 25µl 2x Laemmli sample buffer, 15µl H20 and 1µl unlabeled 
methionine/cysteine (20mM). Viral proteins were then separated by SDS-PAGE on 17.5% gels and 
visualized by fluorography. Protein standards (M) in kDa are given on the left. 
Investigation of the structure showed that Met5 could act as a possible hinge region. 
Manipulation of the φ and ψ-angles of Met5 would bring the P1’ glycine close to the active 
site. Furthermore, the Met5 side chain would end up in close proximity to Lys109 supporting 
the theory that HRV2 2Apro cannot bear a positively charged amino acid at position P5’ (Figure 
4-8A). Sequence analysis revealed that Lys109 is conserved among group A viruses whereas an 
isoleucine is found in the equivalent position of HRV14 2Apro. Therefore, we wanted to 
investigate the influence of the single mutation methionine to arginine at position P5’. 
Mutating Lys109 to isoleucine should then reveal if this residue is involved in this mechanism. 
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Figure 4-8 (A) Crystal structure of HRV2 2Apro. The N-terminus is turned away from the 
active site (Cys 106, depicted in red). Rotation around Met5 (purple) could bring the N-terminus close to 
the active site. This rotation possibly would bring Met5 in proximity to Lys109 (yellow) (generated with 
the “protein movie generator” (Autin and Tuffery 2007)). (B) Multiple sequence alignment of 2Apro 
sequences of several HRV serotypes. Methionine is the predominant residue at position P5’ in Group A 
viruses whereas an arginine is found at P5’ of HRV14 (a group B virus). Lysine at position 109 in HRV2 
2Apro is conserved among the listed Group A viruses. In HRV14 this position is taken by an isoleucine 
(generated with JalView (Clamp et al. 2004)). 
Figure 4-7C shows that the sole introduction of arginine instead of methionine at P5’ 
does not influence self-processing, arguing against our theory that HRV2 2Apro cannot accept 
arginine at P5’. Self-processing of this mutant is comparable to the wild-type kinetics. Self-
processing at wild-type levels by the corresponding mutant K109I was therefore not surprising 
(Figure 4-9A). Figure 4-9B shows the result of the reverse experiment in which isoleucine at 
position 112 was substituted with lysine in HRV14 2Apro. Self-processing of this mutant is 
strongly impaired. First cleavage products could only be detected after 30 minutes and 50% of 
processing was reached between 120 and 180 minutes. This fact indicates a difference in the 
2A proteinases of HRV2 and HRV14. However, in the absence of a HRV14 2Apro structure the 
reason for this difference remains doubtful. 
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Figure 4-9 Role of Lys109 in HRV2 2Apro and Ile112 in HRV14 2Apro in contributing to a 
possible hinge region around P5’. Underlined residues differ from the residues found in the wild-type 
cleavage site. Rabbit reticulocyte lysate was programmed with RNA coding for VP1-2Apro (10ng/µl) and 
incubated at 30°C. Negative controls were prepared by adding water instead of RNA. 10µl aliquots were 
taken at the given time points and put on an icecold mix of 25µl 2x Laemmli sample buffer, 15µl H20 and 
1µl unlabeled methionine/cysteine (20mM). Viral proteins were then separated by SDS-PAGE on 17.5% 
gels and visualized by fluorography. Protein standards (M) in kDa are given on the left. 
4.5 CONSTRUCTION OF HRV14/2 2APRO HYBRIDS 
The experiments in the previous chapters show that the 2A proteases of HRV2 and 
HRV14 show some noticeable differences. The cleavage sites in their self-processing reaction 
differ quite strongly. HRV2 2Apro cleaves at IleIleThrThrAla*GlyProSerAsp, whereas HRV14 2Apro 
cleaves at AspIleLysSerTyr* GlyLeuGlyPro. Additionally, it has been shown that HRV2 2Apro 
cannot accept the HRV14 cleavage site and vice versa (Schertler 2008). The need for proline at 
P2’ in HRV2 2Apro seems to be one reason for the discrimination of the HRV14 cleavage site by 
HRV2 2Apro (see section 4.2). Furthermore, sequence alignments show that the N-terminal 
region of group B viruses exhibits two additional residues in respect to group A viruses (Figure 
4-4B). In section 4.4 we found that the two proteinases showed different response to mutating 
the equivalent residues 109 (HRV2) or 112 (HRV14). Finally, Deszcz et al. have shown that the 
2A proteinases of HRV2 and HRV14 show different responses to the specific 2Apro inhibitor 
zVAM.fmk (Deszcz et al. 2006). zVAM.fmk inhibits both, the self-processing and trans 
cleavages of HRV14 2Apro, whereas HRV2 2Apro is only inhibited in its trans reaction. 
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Figure 4-10 Construction of a hybrid 2Apro. (A) MfeI sites were introduced into the 
plasmids coding for either HRV2 or HRV14 VP1-2Apro. MfeI and BamHI sites were then used to substitute 
the C-terminal domain and create a hybrid containing HRV14 VP1, the N-terminal 2Apro domain of 
HRV14 and the C-terminal 2Apro domain of HRV2. The sequence at the changeover is given separately. 
(B) Scheme of the two domains of HRV2 2Apro. In a hybrid 2Apro the grey N-terminal domain will be 
exchanged by the respective HRV14 2Apro domain. The catalytic triad (numbered according to HRV2 
2Apro) is colored in red (Cys106) and yellow (His18 and Asp35) (generated with the “protein movie 
generator” (Autin and Tuffery 2007)). 
These findings suggest that the two proteinases do not only differ in substrate 
specificity, but could also differ in the general mechanism in which they perform self-
processing. The construction of hybrid 2A proteinases could be a helpful tool to understand 
these differences. 
Thus, we decided to construct a hybrid VP1-2Apro made up of HRV14 VP1, the N-
terminal 2Apro domain of HRV14 and the C-terminal 2Apro domain of HRV2. Introduction of the 
restriction site MfeI was necessary to allow exchange of the cDNA coding for the C-terminal 
HRV2 2Apro domain (Figure 4-10A). The two domains of 2Apro are combined at the end of the 
long interdomain loop at the amino acid Asn56 (Figure 4-10B). Therefore, the construction 
should not interfere with interactions of residues within one domain. 
Figure 4-11A shows self-processing of the hybrid. No cleavage product could be 
detected, indicating that the hybrid was absolutely unable to perform self-processing. Most of 
the interactions involved in substrate recognition are found in the C-terminal domain of 2Apro. 
We therefore introduced the HRV2 cleavage site into the hybrid and tested for self-processing. 
Nevertheless, also this variant was absolutely inactive as no cleavage product could be 
detected even at 300 minutes (Figure 4-11B). 
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Figure 4-11 Self-processing of HRV14/2 hybrid 2Apro on (A) the HRV14 cleavage site and 
(B) the HRV2 cleavage site. Underlined residues differ from the residues found in the wild-type HRV14 
cleavage site. Rabbit reticulocyte lysate was programmed with RNA coding for VP1-2Apro (10ng/µl) and 
incubated at 30°C. Negative controls were prepared by adding water instead of RNA. 10µl aliquots were 
taken at the given time points and put on an icecold mix of 25µl 2x Laemmli sample buffer, 15µl H20 and 
1µl unlabeled methionine/cysteine (20mM). Viral proteins were then separated by SDS-PAGE on 17.5% 
gels and visualized by fluorography. Protein standards (M) in kDa are given on the left. 
4.6 DOES THE VIRAL PROTEIN 2B INFLUENCE 2APRO SELF-
PROCESSING? 
Recently, the group of Karla Kirkegaard showed that the viral protein 2B may influence 
the activity of 2Apro. Poliovirus was grown in the presence of the specific 2Apro inhibitor 
zVAM.fmk. The search for escape mutants revealed that resistance to zVAM.fmk did not 
predominantly map to 2Apro but 2B, indicating that 2B is involved in 2Apro activity (Kirkegaard 
K., pers. comm.). Therefore, we wanted to investigate the influence of 2B on self-processing. 
Furthermore, we were interested if the presence of 2B would influence the diverse ability of 
zVAM.fmk to inhibit HRV2 2Apro and HRV14 2Apro in the self-processing reaction. To this end, 
HRV2 2B and HRV14 2B were amplified from full length clones by standard PCR techniques and 
cloned into the respective plasmids downstream of 2Apro. The resulting VP1-2Apro-2B 
constructs were tested for their self-processing activity. 
Self-processing of HRV2 VP1-2Apro-2B is shown in Figure 4-12A. First cleavage products 
were detected at 20 minutes after start of translation. 50% cleavage of the precursor was 
achieved at about 60 minutes and cleavage was practically finished after 300 minutes. Thus, 
HRV2 VP1-2Apro-2B performs self processing slower than the HRV2 VP1-2Apro construct 
(compare Figure 4-1A). Proper folding of the precursor probably takes longer in the presence 
of 2B, giving an explanation for the delayed kinetics. HRV14 VP1-2Apro-2B exhibits a similar 
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pattern (Figure 4-12B). First cleavage products were detected after 20 minutes and the time 
point of 50% cleavage was found at about 120 minutes. This finding is consistent with the fact 
that also HRV14 VP1-2Apro is slightly slower than HRV2 VP1-2Apro. Thus, the VP1-2Apro-2B 
constructs exhibit normal self-processing albeit being slightly slower than the VP1-2Apro 
constructs. 
 
 
Figure 4-12 Self-processing of (A) HRV2 and (B) HRV14 VP1-2Apro-2B constructs. Rabbit 
reticulocyte lysate was programmed with RNA coding for VP1-2Apro-2B (10ng/µl) and incubated at 30°C. 
Negative controls were prepared by adding water instead of RNA. 10µl aliquots were taken at the given 
time points and put on an icecold mix of 25µl 2x Laemmli sample buffer, 15µl H20 and 1µl unlabeled 
methionine/cysteine (20mM). Viral proteins were then separated by SDS-PAGE on 17.5% gels and 
visualized by fluorography. Protein standards (M) in kDa are given on the left. 
An erroneous primer for PCR amplification of HRV14 2B gave rise to a HRV14 VP1-
2Apro-2B construct with a mutation in the C-terminal region of 2B (I94N). Surprisingly, this 
single mutation totally stopped 2Apro from performing self-processing, strongly supporting the 
idea that 2B is involved in 2Apro activity (Figure 4-13). 
 
 
Figure 4-13 Self-processing of HRV14 VP1-2Apro-2B with the mutation I94N in 2B. Rabbit 
reticulocyte lysate was programmed with RNA coding for VP1-2Apro-2B (10ng/µl) and incubated at 30°C. 
Negative controls were prepared by adding water instead of RNA. 10µl aliquots were taken at the given 
time points and put on an icecold mix of 25µl 2x Laemmli sample buffer, 15µl H20 and 1µl unlabeled 
methionine/cysteine (20mM). Viral proteins were then separated by SDS-PAGE on 17.5% gels and 
visualized by fluorography. Protein standards (M) in kDa are given on the left. 
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In next step, we wanted to test whether the presence of 2B influences the ability of 
zVAM.fmk to inhibit HRV14 2Apro in cis. mRNA coding for HRV14 VP1-2Apro-2B was used to 
program RRL’s in the presence of different amounts of the specific 2Apro inhibitor zVAM.fmk. 
Samples were incubated for 60 minutes followed by the addition of ice-cold Laemmli sample 
buffer and unlabeled methionine/cysteine in order to stop translation. zVAD.fmk (a caspase 
inhibitor found to be also active against 2Apro) served as a positive control, 0.1% 
dimehtylsulfoxide (serves as the solvent for zVAM.fmk) as a negative control. Figure 4-14A 
shows that there is no significant difference between the increasing amounts of zVAM.fmk and 
when compared to the controls. Furthermore, the time point of 60 minutes seemed to be not 
optimal. In order to test if the inhibitors were active at all, we tested them under the 
conditions described by Deszcz et al. (Deszcz et al. 2006). We used mRNA coding for HRV14 
VP1-2Apro to program RRL’s. Additionally we tested a fresh stock of zVAD.fmk as a positive 
control (indicated by zVADnew). Figure 4-14B shows that only the highest concentration of 
zVAM.fmk was able to induce slight inhibition. However, according to Deszcz et al. sufficient 
inhibition should already be achieved at a concentration of 50µM indicating that the inhibitor 
was out of date and not active any more. This was supported by the finding that the fresh 
stock of zVAD.fmk did indeed inhibit self-processing of HRV14 VP1-2Apro in the positive control. 
 
 
Figure 4-14 Inhibition of (A) HRV14 VP1-2Apro-2B and (B) HRV14 VP1-2Apro self-processing 
by zVAM.fmk and zVAD.fmk. Rabbit reticulocyte lysate was programmed with RNA coding for VP1-2Apro-
2B and VP1-2Apro respectively (10ng/µl) and incubated at 30°C. Negative controls were prepared by 
adding water instead of RNA. The indicated amount of inhibitor was added 10 minutes after start of 
translation. Reaction was stopped after 60 minutes by adding an icecold mix of 25µl 2x Laemmli sample 
buffer, 15µl H20 and 1µl unlabeled methionine/cysteine (20mM). Viral proteins were then separated by 
SDS-PAGE on 17.5% gels and visualized by fluorography. Protein standards (M) in kDa are given on the 
left. 
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4.7 METHIONINE AT POSITION 143 IN LBPRO EXHIBITS 
COMPARABLE PERFORMANCE IN DISCRIMINATING 
PHENYLALANINE FROM P2 THAN LEUCINE AT POSITION 143 
FMDV codes for an additional protein preceding the genes for the structural proteins, 
the leader protease Lbpro. It is thought that in the initial self-processing reaction it cleaves itself 
off the polyprotein in an intramolecular reaction, although also intermolecular cleavage cannot 
be ruled out. Figure 4-15A shows the self-processing of the wild-type enzyme on its wild-type 
substrate. No precursor could be detected, demonstrating a very fast and efficient cleavage. 
Lbpro codes for four methionines whereas VP4-VP2 has only two. Therefore, the intensity of the 
Lbpro band is stronger than the VP4-VP2 band. 
 
 
Figure 4-15 Self-processing of (A) FMDV Lbpro-VP4-VP2 wild-type and (B-D) variants 
carrying the mutation L143M. Rabbit reticulocyte lysate was programmed with RNA coding for Lbpro-
VP4-VP2 (10ng/µl) and incubated at 30°C. Negative controls were prepared by adding water instead of 
RNA. 10µl aliquots were taken at the given time points and put on an icecold mix of 25µl 2x Laemmli 
sample buffer, 15µl H20 and 1µl unlabeled methionine/cysteine (20mM). Viral proteins were then 
separated by SDS-PAGE on 17.5% gels and visualized by fluorography. Protein standards (M) in kDa are 
given on the left. 
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Recently, it has been shown that the leader protease is not able to process in cis the 
cleavage site AlaAspPheGly*ArgGlnThrPro present on eIF4GII (Kuehnel et al. 2004). Kühnel et 
al. found that it was phenylalanine at P2 and aspartic acid at P3 that caused the discrimination. 
Leucine 143, found in the hydrophobic S2 pocket, was identified as preventing phenylalanine 
from protruding deeper into the pocket. Hence, substitution of leucine 143 by alanine 
rendered Lbpro able to cleave a substrate with phenylalanine at P2 (Mayer et al. 2008). 
However, although Leucine 143 is not conserved among the seven serotypes of FMDV (Figure 
4-16), the only other amino acids found at this position are isoleucine and methionine, which 
possess bulky and hydrophobic side-chains like leucine. 
 
 
Figure 4-16 Multiple sequence alignment of Lbpro sequences of one strain of each FMDV 
serotype. The bulky hydrophobic residues leucine, methionine and isoleucine can be found at position 
143 (purple). Only leucine or valine is found in all sequenced FMDV strains at position 200 (P2) (orange) 
(generated with JalView (Clamp et al. 2004)). 
Therefore, we wanted to investigate if methionine at position 143 would also be able 
to discriminate phenylalanine from the S2 pocket. Substitution of leucine 143 with methionine 
had no influence on the self-processing of the wild-type cleavage site (Figure 4-15B). No 
precursor could be detected, which is comparable with the wild-type enzyme. The L143M 
mutant was however impaired in its ability to cleave the substrate with phenylalanine at P2 
(Figure 4-15C). The precursor could still be detected 30 minutes after start of translation. 
Additionally, an aberrant cleavage product could be detected at 60 minutes (labeled by arrow). 
However, comparison of the self-processing of the wild-type enzyme on the same cleavage 
sites shows that the L143M mutant is less impaired then the wild-type enzyme (Mayer et al. 
2008). Finally, processing of the eIF4GII sequence AlaAspPheGly*ArgGlnThrPro by the L143M 
variant is severely impaired (Figure 4-15D) and is comparable to the self-processing activity of 
the wild-type enzyme on the same cleavage site. Cleavage products could not be detected 
before 30 minutes after start of translation. Moreover, additional aberrant cleavage products 
were detected. 
5 DISCUSSION 
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The cleavage sites of HRV 2A proteinases vary amongst the different serotypes in the 
self-processing reaction. Furthermore, it was shown that 2Apro cleavage sites for trans-
cleavages vary even more than for cis-cleavages. For example, HRV2 2Apro cleaves its own 
polyprotein at IleIleThrThrAla*GlyProSerAsp whereas HRV14 2Apro cleaves at 
AspIleLysSerTyr*GlyLeuGlyPro. The two isoforms of eukaryotic initiation factor 4G (eIF4GI and 
eIF4GII) are cleaved at ThrLeuSerThrArg*GlyProProArg (Lamphear et al. 1993) and 
ProLeuLeuAsnVal*GlySerArgArg (Gradi et al. 2003) in trans by HRV2 2Apro. The cleavage sites 
on eIF4GI and II used by HRV14 2Apro have not been determined yet but are thought to be 
identical. Table 5-1 gives an overview of some serotypes and their respective cleavage sites on 
the polyprotein. 
The strong variation of the cleavage sites makes it impossible to create a consensus 
sequence for HRV 2Apro cleavage sites. HRV 2A proteinases vary in their substrates in cis and 
trans and are known to cleave several cellular proteins (Badorff et al. 1999, Joachims et al. 
1999, Kerekatte et al. 1999, Seipelt et al. 2000, Park et al. 2008). Nevertheless, there are some 
requirements that render 2Apro a specific proteinase such as the strong requirement for glycine 
at P1’ or the preference of HRV2 2Apro for threonine at P2. Lacking HRV 2Apro structures bound 
to substrates or inhibitors and with only one human rhinoviral structure of 2Apro available 
(Petersen et al. 1999), mutational analysis of the cleavage site plays an essential role in 
determining the exact substrate requirements of HRV 2Apro. 
 
Serotype VP1 ? 2Apro 
HRV 1B SMKTV  GPSD 
HRV 2 IITTA  GPSD 
HRV 9 AVKNV  GPSD 
HRV 85 SLTTA  GPSD 
HRV 89 TVTNV  GPSS 
HRV 14 DIKSY  GLGP 
Table 5-1 Amino acid sequences at the VP1-2Apro junctions of different HRV serotypes. 
Recently, it has been shown that 2Apro could be an important target for the 
development of antiviral drugs (Crowder and Kirkegaard 2005). Co-transfection of RNA coding 
for wild-type PV and a mutant that was unable to process the VP1-2Apro junction (2Apro C109R) 
resulted in a dominant-negative effect, inhibiting the replication of the wild-type virus. A 
similar effect is imaginable for the FMDV leader proteinase. Therefore, understanding of the 
substrate specificities of 2Apro and Lbpro is crucial for the development of new inhibitors. 
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5.1 HRV2 2APRO CANNOT ACCEPT THE VP1-2APRO CLEAVAGE SITE 
OF HRV14 
HRV2 2Apro is not able to self-process at the VP1-2Apro junction when the wild-type 
cleavage site is replaced by the cleavage site of HRV14 (AspIleLysSerTyr*GlyLeuGLyPro). We 
therefore wanted to investigate which of the residues in the HRV14 cleavage site were 
responsible for this discrimination. Comparison of the two cleavage sites shows that the major 
differences can be found at the positions P5, P3, P1, P2’, P3’ and P4’ (Table 5-1). 
Sommergruber et al. showed that peptides with tyrosine at P1 were cleaved with even higher 
efficiency than peptides with the wild-type alanine by HRV2 2Apro (Sommergruber et al. 1992), 
indicating that tyrosine at P1 should not be the reason for the discrimination of the HRV14 
cleavage site. When the crystal structure of HRV2 2Apro was solved, a peptide, spanning P5 to 
P1’, was modeled into the substrate binding cleft (Petersen et al. 1999). In this model, the 
main chain of threonine at P3 is hydrogen bonded to the main chain of Gly124. Its side chain 
points away from the substrate binding cleft. Based on this model, it is quite possible that 
lysine is well accepted at the P3 position and is therefore also thought to be not responsible 
for the inability of HRV2 2Apro to accept the HRV14 cleavage site. Thus, investigation of the P’ 
region seemed to be most interesting. 
An interesting feature in the P’ region of HRV2 2Apro is a stable type I reverse turn that 
is stabilized by a hydrogen bond between the carboxylate of Asp4 and the protonated α-amino 
group of Gly1 (Petersen et al. 1999). Additionally, the N-terminus is rotated out of the active 
site in the crystal structure. It has been speculated that this stable turn serves as a protection 
against product inhibition. However, this motif is not conserved. Furthermore, HRV2 2Apro 
could easily process the cleavage site with proline instead of aspartic acid at P4’ (Figure 4-2B). 
Therefore, the reverse turn or at least its stabilization by a hydrogen bond does not seem to be 
necessary for self-processing. As introduction of the HRV14 residues LeuGlyPro at P2’-P4’ only 
slightly decreased the self-processing activity of HRV2 2Apro (Figure 4-2C), the P’ region seemed 
not to be a major determinant of substrate specificity. However, it has been reported that 
peptides with phenylalanine, threonine, lysine or aspartic acid at P2’ are cleaved 2-5 fold less 
efficiently than peptides with proline (Sommergruber et al. 1992). Thus, it seems possible that 
the mutation of proline to leucine is responsible for the slight decrease in self-processing 
efficiency. 
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As a consequence, we started to concentrate on the P region and were surprised to 
find that also mutating P3-P1 did not significantly alter cleavage efficiency (Figure 4-2D). 
Especially serine at P2 is known to be not well accepted by HRV2 2Apro at least in trans. 
Sommergruber et al. showed that a peptide with serine at P2 was cleaved with a relative 
efficiency of only 0.15 in respect to the peptide with the wild-type cleavage sequence 
(Sommergruber et al. 1992). However, tyrosine at P1 was shown to be even better accepted 
than the wild-type alanine. Therefore, the presence of tyrosine at P1 is possibly compensating 
the harmful effect of serine at P2. 
Neither the introduction of HRV14 residues at the P3-P1 region nor mutating the P2’-
P4’ region alone severely impaired self-processing. A combination of mutations at both sides 
of the cleavage site seems to be required to stop HRV2 2Apro from performing the cis reaction 
(Figure 4-3). The most severe effect could be obtained by maintaining the mutations at P3-P1 
and additionally mutating proline at P2’ to leucine (Figure 4-3C). Furthermore, the finding that 
cleavage was still severely impaired when the wild-type residue threonine was reintroduced at 
P3 does not disagree with the idea that lysine is well accepted at P3 (Figure 4-3D). If lysine at 
P3 would contribute to the discrimination of the HRV14 cleavage site, one would expect an 
increase in self-processing activity upon reintroduction of the wild-type residue. However, as 
both cleavage sites are not processed at all, a contribution of lysine cannot be totally excluded. 
In contrast to our initial assumptions, these experiments showed that the P’ region indeed 
seems to be important in the recognition of the substrate. Investigation of the HRV2 2Apro 
structure revealed a putative S2’ pocket made up of Arg15, Leu19, Phe20, Tyr39 and the main 
chain atoms of Asn16 (Figure 4-4A). Amongst these residues, Arg15 was found to be conserved 
within group A viruses whereas in group B viruses a conserved methionine was found at the 
equivalent position. However, mutating Arg15 to methionine did not significantly affect 
processing on the respective cleavage site (Figure 4-5A) indicating that Arg15 is not involved in 
the recognition of the P2’ residue. Leu19 and Asn16 are conserved among group A and group B 
viruses. Thus, it seems that our prediction about the S2’ pocket was incorrect. 
However, the importance of proline at P2’ in HRV2 2Apro may arise from its fixed φ-
angle. Through this fixed angle, it possibly stabilizes the type I reverse turn of the N-terminus, 
shaping the substrate into the correct formation to reach the active site. In contrast, the N-
terminus of HRV14 2Apro exhibits two additional amino acids. Thus, there would be no need for 
a tight turn in the substrate. Notably, the 3C proteinases (chymotrypsin-like proteinases like 
2Apro) of HRV2, HRV14 and PV1 also show preference for proline at P2’ and an absolute 
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requirement for glycine at P1’. Investigation of the atomic structures (Matthews et al. 1994, 
Mosimann et al. 1997, Matthews et al. 1999) revealed that glycine and proline are probably 
responsible for a turn in the substrate that prevents clashing of the substrate with the β-strand 
bΙ1 (Semler and Wimmer 2002). As 2Apro and 3Cpro are thought to have arisen by gene 
duplication (Petersen et al. 1999), these findings support the theory that proline at P2’ could 
be important for a special turn in the substrate in HRV2 2Apro, even though 2Apro lacks the 
mentioned β-strand bΙ1. However, Sommergruber et al. found that a peptide corresponding to 
P8-P2’ was nearly cleaved as efficiently as a peptide corresponding to P8-P8’. In contrast, a P8-
P1’ peptide was cleaved at a 30-fold reduced rate, indicating that the residue at P2’ also 
strongly contributes to the binding affinity of the substrate to the enzyme (Sommergruber et 
al. 1992). However, in the absence of a 2Apro structure with the substrate bound to the active 
site, this theory will remain just speculation. 
5.2 NUP62 CONTAINS SEQUENCES THAT WERE FOUND TO BE 
CLEAVED IN TRANS BUT CANNOT BE ACCEPTED IN CIS BY 
HRV2 2APRO 
Recently, it has been shown that proteins of the nuclear pore complex (NUPs) are 
cleaved upon poliovirus infection and that HRV2 2Apro was able to induce cleavage of Nup98 in 
HeLa whole cell lysates (Park et al. 2008). Additionally, in vitro studies of Nup62 cleavage by 
HRV2 2Apro identified multiple cleavage sites. Table 4-2 lists selected Nup62 cleavage sites in 
which alanine can be found at P1’ and P2’ and compares them with the wild-type cleavage site 
for 2Apro self-processing (Park N. and Gustin K., pers. comm.). 
The two cleavage sites giving rise to the fragments ND/cp5 and ND/cp6 contain alanine 
at P2’. Cleavage at these sites is not surprising as the cleavage sites fulfill the requirements of 
substrate specificity at the positions P4, P2 and P1’ very well. These finding also correlates with 
the results presented in this thesis. The exclusive mutation of P2’-P4’ (Figure 4-2C) or the 
single mutation of proline at P2’ to alanine (Figure 4-6A) did not affect self-processing 
significantly. However, the fact that Nup62 is cleaved at the cleavage sites giving rise to 
ND/cp3 and cp8/cp1 indicates that the substrate requirements for cis and trans-cleavages can 
differ. Both cleavage sites lack glycine at P1’ (mutated to alanine) and exhibit a poorly 
recognized residue at P2 (Sommergruber et al. 1992). In addition, the Nup62 cp8/cp1 cleavage 
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site contains alanine at P2’. Still, both of these cleavage sites were found to be cleaved in 
trans. In contrast, alanine at P2’ in combination with the non-optimal residue serine at P2 
severely impaired self-processing (Figure 4-6B) and HRV2 2Apro was also not able to accept 
alanine at P1’ in the cis reaction (Figure 4-6C). 
Like 2Apro, 3Cpro has an absolute requirement for glycine at P1’. Phe25 situated on β-
strand bΙ1 of 3Cpro was proposed to be responsible for the discrimination against all other 
residues at P1’ by occupying the space that would be needed by a side chain (Semler and 
Wimmer 2002). The same role was postulated for Leu19 of 2Apro (Petersen et al. 1999). Indeed, 
superimposition of the structures of HRV2 2Apro and 3Cpro strengthen this theory. The two 
structures superimpose with an rms-value of 1.25Å using the “Magic Fit” tool of the 
“DeepView – Swiss pdb viewer” (Guex and Peitsch 1997). The catalytic triad is found to 
superimpose very well. Additionally, the side chains of Phe25 and Leu19 are found to occupy 
the same space albeit arising from different β-strands. However, we show here that mutating 
Leu19 to alanine is not sufficient to restore self-processing on a substrate that contains alanine 
at P1’. Thus, Leu19 is at least not the only residue that is contributing to the discrimination of 
any side chains at P1’. To our knowledge, the corresponding mutation F25A in HRV2 3Cpro has 
not been tested so far. Therefore, data for comparison is unfortunately missing. It was also 
suggested that His18 itself and maybe Tyr85 could act as determinants for the specificity at 
P1’. Tyr85 was proposed to be rotated around its Cα-Cβ bond during self processing, bringing it 
into a position where it could maybe influence substrate specificity at P1’ (Petersen et al. 
1999). Tyr85 is part of the so-called dityrosine flap that includes two tyrosines that are 
conserved amongst the 2A proteinases of rhinoviruses and enteroviruses. However, a 2Apro 
structure with the substrate bound to the enzyme will be needed to reveal why only glycine 
can be accepted in the self-processing reaction while alanine can be accepted during trans-
cleavages. 
5.3 MET5: A HINGE AT WHICH THE N-TERMINUS IS ROTATED INTO 
THE ACTIVE SITE DURING SELF-PROCESSING? 
As described in part 4.4, Skern et al. showed that a peptide with the sequence 
IVTRPIITTA*GPGPRYGGVG (underlined residues are the ones found in the equivalent positions 
of the HRV14 VP1-2Apro junction) is not cleaved by HRV2 2Apro (Skern et al. 1991). We showed 
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that this sequence (plus a variant of it) could also not be accepted in the self-processing 
reaction (Figure 4-7A and B). Residues seven and eight form β-strand bΙ2 of HRV2 2Apro. Thus, 
mutation of these two residues was likely to interfere with the structure of the proteinase and 
hence with its activity. Nevertheless, the sequence is also not accepted in experiments with 
peptides in which these residues of the substrate do not need to form this β-strand. Thus, we 
focused our interest on the P2’-P5’ region. Previous results had shown that mutations at P2’-
P4’ without additional mutations in the P3-P1 region had no dramatic effect on self-processing. 
Therefore, the presence of the bulky charged residue of arginine at position P5’ instead of the 
wild-type methionine attracted our attention. 
Sequence analysis revealed that methionine is the predominant amino acid at P5’ in 
group B viruses, although methionine is not completely conserved (Figure 4-8B). Furthermore, 
Petersen et al. have already proposed that the region at Met5 could act as a hinge region at 
which the substrate is turned into the active site during self-processing (Petersen et al. 1999). 
We thought that rotation around this region would probably result in positioning the side 
chain of Met5 close to Lys109, supporting our theory that arginine at P5’ could be responsible 
for the inability to self-process at the cleavage sites mentioned above. Additionally, Lys109 is 
conserved amongst group A viruses whereas in HRV14 this position is occupied by isoleucine. 
However, it should be mentioned that if only the φ and ψ angles of Met5 are adjusted in order 
to roughly fit the substrate into the active site, they will be found in forbidden regions in the 
ramachandran-plot (Figure 5-1). Furthermore, the side chain of Asp4 would clearly clash into 
the main chain of Asp105 and Cys106 (Figure 5-2). Nonetheless, the side chains of Met5 and 
Lys109 would clearly end up close together. 
 
 
 
 
 
 
 
 
 
 
 
 
87 Discussion 
 
Figure 5-1 Ramachandran plot of Met5 in HRV2 2Apro. In the crystal structure (PDB 2HRV) 
Met5 is found in an allowed region in the ramachandran plot (blue). Rotating the N-terminus into the 
active site around Met5 leads to a shift into a forbidden region (red). 
 
 
Figure 5-2 Structure of HRV2 2Apro with the substrate rotated into the active site. 
Rotation was performed using the swiss pdb viewer (Guex and Peitsch 1997). Only the φ/ψ angles of 
Met5 have been adjusted. The active site cysteine is shown in red. The N-terminal five residues that are 
moved from their original position are depicted in blue (generated with the “protein movie generator” 
(Autin and Tuffery 2007)). 
Unfortunately, the results of our mutational analysis disagreed with our proposed 
repulsion of arginine at P5’ and Lys109. A cleavage site with the single mutation Met5 to 
arginine was processed at wild-type levels by HRV2 2Apro (Figure 4-7C). Thus, not surprisingly 
the mutant K109I exhibited unaffected self-processing. Interestingly, the reverse mutant in 
Residue φ ψ 
Met 5 -87.0 48.3 
Altered Met5 -44.1 -137.8 
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which the equivalent residue Ile112 of HRV14 2Apro was mutated to lysine exhibited severely 
impaired self-processing, indicating a contribution to substrate recognition by this residue. 
However, as mentioned before, HRV14 2Apro exhibits two additional amino acids in its N-
terminal region in respect to the N-terminal region of HRV2 2Apro. Thus, it is doubtful whether 
Met5 of HRV2 2Apro and Arg5 of HRV14 2Apro occupy equivalent positions in the structure as in 
the sequence alignment Met5 aligns with Gly7 of HRV14 2Apro. 
Recently, the solution structure of coxsackievirus B4 (CVB4) 2Apro was solved (Baxter et 
al. 2006). This NMR-structure and the crystal structure of HRV2 2Apro are the only 2Apro 
structures available so far. Superimposition of the HRV2 2Apro structure and the CVB4 2Apro 
structure shows that Gly8 of CVB4 2Apro is in the equivalent structural position to Met5 of 
HRV2 2Apro. The fact that Gly7 of HRV14 aligns with Met5 of HRV2 2Apro and Gly8 of CVB4 2Apro 
(Figure 5-3) strongly implies that Gly7 and not Arg5 of HRV14 2Apro is in the equivalent 
structural position to Met5 in HRV2 2Apro. 
 
 
Figure 5-3 Sequence alignment of the 2Apro sequences of HRV2, HRV14 and 
coxsackievirus B4. 
In contrast to HRV2 2Apro, a molecular model of CVB4 2Apro self-processing is available. 
Baxter et al. modeled the substrate including the C-terminal eight residues of VP1 into the 
active site of the CVB4 2Apro structure. This model shows that the substrate region of P3’-P8’ 
forms a quite wide bulge with the side chains of Tyr3, His5, Gln6 and Ser7 exposed to the 
solvent. We investigated this model to evaluate whether a rotation around Gly8 is needed for 
the N-terminus to reach the active site in CVB4 2Apro. Unfortunately, the φ/ψ angles of Gly8 
vary quite strongly within the 17 NMR-structures of the CVB4 2Apro that are deposited in the 
protein data base (PDB 1Z8R) (Table 5-2, Figure 5-4). Therefore, it is hard to judge whether a 
rotation around Gly8 in CVB4 2Apro is needed for self-processing. 
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Molecule Residue φ ψ 
1Z8R_1 GLY8 63.7 23.2
1Z8R_2 GLY8 -157.3 37.8
1Z8R_3 GLY8 166.8 -51.6
1Z8R_4 GLY8 -156.6 140.8
1Z8R_5 GLY8 -161.3 -76.0
1Z8R_6 GLY8 97.2 84.0
1Z8R_7 GLY8 158.6 -28.5
1Z8R_8 GLY8 -170.8 60.4
1Z8R_9 GLY8 -160.1 179.3
1Z8R_10 GLY8 152.4 -36.1
1Z8R_11 GLY8 178.7 37.4
1Z8R_12 GLY8 140.1 -25.1
1Z8R_13 GLY8 -160.6 27.4
1Z8R_14 GLY8 143.1 -40.9
1Z8R_15 GLY8 -135.2 27.2
1Z8R_16 GLY8 169.4 43.5
1Z8R_17 GLY8 96.8 -29.6
1Z8R with modeled substrate GLY8 -79.0 125.5
Table 5-2 φ/ψ angles of Gly8 in the 17 molecules of the CVB4 2Apro NMR-structure 
(1Z8R) as well as in the structure with the substrate modeled into the active site. 
 
Figure 5-4 Ramachandran plot of Gly8 residues of the 17 CVB4 2Apro NMR structures 
deposited in the PDB file 1Z8R as well as of Gly8 of a structure with the N-terminus modeled into the 
active site (also see Table 5-2). The φ/ψ angles exhibit strong variation which makes it hard to judge 
whether rotation around Gly8 is needed for the N-terminus to reach the active site. 
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5.4 CONSTRUCTION OF HRV14/2 2APRO HYBRIDS 
The construction of a hybrid 2A proteinase was intended to be a useful tool to 
investigate the differences of HRV2 and HRV14 2A proteinases. The N-terminal domain of 
HRV14 2Apro was fused with the C-terminal domain of HRV2 2Apro at the interdomain loop. 
Consequently, the catalytic triad of each enzyme was split. The general base His20 and Asp38 
are provided by the N-terminal HRV14 domain whereas the nucleophilic cysteine (now Cys109) 
is provided by the C-terminal HRV2 domain. This arrangement is one of several possible 
reasons why the hybrid 2Apro was not able to perform self-processing. If the interactions 
between the two domains of the hybrid 2Apro are not optimal, it is likely that a correct 
orientation of the catalytic triad is not possible. The total sequence identity between HRV2 and 
HRV14 2Apro is only 40%. Figure 5-5A shows residues located at the interface between the two 
domains of HRV2 2Apro. The sequence alignment (Figure 5-5B) shows that these residues are 
not very well conserved. Thus, it seems likely that the N-terminal domain of HRV14 2Apro and 
the C-terminal domain of HRV2 2Apro cannot act together to form an active enzyme.  
A second possible reason for the inactivity of the hybrid 2Apro is that the HRV14 
cleavage site could not be accepted by the hybrid enzyme. As we have shown that HRV2 2Apro 
cannot accept the HRV14 cleavage site and as we know that the recognition of the P region of 
the substrate is exclusively mediated by residues of the C-terminal domain, this seemed to be 
a likely possibility. However, introduction of the HRV2 cleavage site into the hybrid enzyme did 
not improve self-processing (Figure 4-11B), indicating that the problem goes either beyond 
substrate recognition or that a hybrid substrate containing HRV14 and HRV2 residues is 
needed. In principle it is also possible that the hybrid 2Apro is not at all able to fold correctly. 
Finally, it is worth mentioning that a similar approach by Roetzer A. to construct an active 
hybrid 2Apro between HRV2 2Apro and CVB4 2Apro also failed (Roetzer 2004). Neither the 
construct with an N-terminal HRV2 domain and a C-terminal CVB4 domain nor the inverse 
construct were active in self-processing. 
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Figure 5-5 Residues situated at the interface of the N-terminal and C-terminal domain of 
HRV2 2Apro. (A) Residues situated at the interface and directing towards the opposite domain. Residues 
provided by the N-terminal domain are colored red, those from the C-terminal domain are colored 
green. Residues that are conserved amongst HRV2 and HRV14 2Apro are represented in reverse video. 
Residues Ser33, Leu36, Gly107 and Thr121 are also found at the interface but are hidden in this 
representation (generated with the “protein movie generator” (Autin and Tuffery 2007)). (B) Sequence 
alignment of HRV2 and HRV14 2Apro. Conserved interface residues are given in reverse video (generated 
with JalView (Clamp et al. 2004)). 
5.5 DOES THE VIRAL PROTEIN 2B INFLUENCE 2APRO SELF-
PROCESSING? 
It was stated by Hellen et al. that a VP1-2Apro precursor acts as a representative model 
for investigating self-processing of 2A proteinases (Hellen et al. 1992). In vitro translation of 
mRNA coding for PV1 VP1-2Apro for one hour followed by immunoprecipitation with antiserum 
directed against VP1 or 2Apro showed that only a small amount of precursor remained 
uncleaved. Similar results were achieved when VP1 was replaced by the entire P1 region of 
structural proteins or 2Apro was replaced by most of the P2 region of non-structural proteins. 
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However, recent results suggest that the protein 2B is involved in the self-processing reaction 
(Kirkegaard K., pers. comm.). PV1 mutants that had escaped the treatment with the 2Apro 
specific inhibitor zVAM.fmk exhibited the mutation Y93C in 2Apro as well as the mutations I6V, 
I6M, I2V and T18A in the protein 2B. This theory is further strengthened by the finding that an 
HRV14 VP1-2Apro-2B construct with the mutation I94N in 2B was totally inactive in self-
processing (Figure 4-13). 
Furthermore, we show here that the processing of HRV2 and HRV14 VP1-2Apro-2B 
constructs is delayed in respect to corresponding VP1-2Apro constructs. Hellen et al. reported 
that no more than 5% of uncleaved precursor could be detected upon 60 minutes of 
translation, no matter wether they used a VP1-2Apro construct or a construct made up of VP1 
and nearly the entire P2 region of non-structural proteins. This is in contrast to our own results 
as Figure 4-12 shows that a minimum of 50% of uncleaved precursor could be detected at the 
time point of 60 minutes. 
Deszcz et al. showed that HRV2 2Apro was not sensitive to zVAM.fmk in cis, whereas 
HRV14 2Apro was inhibited in the self-processing reaction (Deszcz et al. 2006). Therefore, we 
also wanted to test whether the presence of 2B influences the sensitivity of the cis reaction to 
zVAM.fmk. However, as we found that our inhibitor stocks seemed to be no longer active, 
these experiments had to be postponed. 
5.6 METHIONINE AT POSITION 143 IN LBPRO EXHIBITS 
COMPARABLE PERFORMANCE IN DISCRIMINATING 
PHENYLALANINE FROM P2 THAN LEUCINE AT POSITION 143 
Recently, it has been found that the leader protease is severely impaired in self-
processing on cleavage sites with phenylalanine at P2 or aspartic acid at P3 (Kuehnel et al. 
2004). Furthermore, Leu143 was identified as a major determinant for the specificity at P2 
(Mayer et al. 2008). Additionally, we were able to show that also methionine, which can be 
found at position 143 of some FMDV strains, is able to discriminate phenylalanine from the S2 
pocket. However, the effect of phenylalanine at P2 is not that severe in the L143M variant than 
in the wild-type enzyme. The nature of the aberrant cleavage products remains unclear. 
Only leucine or valine can be found at the P2 positions of all strains that have been 
sequenced so far. Additionally, position 143 is always occupied by a bulky hydrophobic side 
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chain in all isolates sequenced so far. This suggests that not cleaving substrates with 
phenylalanine at P2 has biological importance for the virus. Therefore, the construction of the 
S2 pocket may strongly contribute to the restricted number of substrates cleaved by Lbpro. 
Indeed, the two isoforms of eukaryotic initiation factor 4G (eIF4GI and eIF4GII) remain the only 
cellular substrates identified so far. 
Like the wild-type enzyme, the L143M mutant was strongly impaired in processing the 
cleavage site ADFG*RQTP. However, it was able to cleave the substrate with the single 
mutation L200F, albeit at a very low rate. Additionally, Mayer et al. have reported that 
mutating Leu143 to alanine could restore some cleavage activity on the ADFG*RQTP substrate, 
but not to wild-type levels (Mayer et al. 2008). These facts support the finding of Kuehnel et al. 
that aspartic acid at P3 also contributes to the discrimination of this cleavage site (Kuehnel et 
al. 2004). Thus, future work should also concentrate on the P3 residue and reveal, how the S3 
pocket is able to discriminate aspartic acid. 
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6.1 ABBREVIATIONS 
 
2Apro Proteinase 2A 
aa Amino acid 
Amp Ampicillin 
bp Base pairs 
cDNA Complementary DNA 
CIP Calf intestine phosphatase 
CITE Cap-independent translation enhancer 
Cp Cleavage product 
CTE C-terminal extension 
CVB Coxsackie virus B 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleotide triphosphate 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
eIF3 Eukaryotic initiation factor 3 
eIF4A Eukaryotic initiation factor 4A 
eIF4E Eukaryotic initiation factor 4E 
eIF4F Eukaryotic initiation factor 4F 
eIF4G Eukaryotic initiation factor 4G 
EM Electron microscopy 
EMCV Encephalomyocarditis virus 
FMDV Foot and mouth disease virus 
HAV Hepatitis A virus 
HeLa cells Henrietta Lacks’ cells 
HRV Human rhinovirus 
ICAM-1 Intercellular adhesion molecule 1 
ICTV International committee on taxonomy of viruses 
IRES Internal ribosomal entry segment 
kb Kilo bases 
kDa Kilo Dalton 
Labpro Leader proteinase ab 
LB Luria Bertani 
Lbpro Leader proteinase b 
LDLR Low density lipoprotein receptor 
LFA-1 Leukocyte function-associated antigen-1 
Lpro Leader proteinase 
LRP Low density lipoprotein receptor related protein 
Mac-1 Macrophage-1 antigen 
mRNA Messenger RNA 
NF-κB Nuclear factor κB 
NMR Nuclear magnetic resonance 
NTP Nucleotide triphosphate 
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NUP Nuclear pore complex protein 
ORF Open reading frame 
PABP Poly-A binding protein 
PAGE Polyacrylamide gel electrophoresis 
PCR Polymerase chain reaction 
PNK Polynucleotide kinase 
pol Polymerase 
Poly-A Poly adenylation 
PV Poliovirus 
RNA Ribonucleic acid 
RRL Rabbit reticulocyte lysate 
SDS Sodiumdodecylsulfate 
TAE Tris-acetate-EDTA 
TE Tris-EDTA 
UTR Untranslated region 
UV Ultra-violet 
VLDLR Very low density lipoprotein receptor 
VP1-4 Viral protein 1-4 
VPg Viral protein genome linked 
wt Wild-type 
zVAD.fmk Benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone 
zVAM.fmk Benzyloxycarbonyl-Val-Ala-Met-fluoromethylketone 
6.2 LIST OF AMINO ACIDS 
 
G Gly Glycine 
A Ala Alanine 
V Val Valine 
L Leu Leucine 
I Ile Isoleucine 
M Met Methionine 
P Pro Proline 
S Ser Serine 
T Thr Threonine 
C Cys Cysteine 
H His Histidine 
F Phe Phenylalanine 
Y Tyr Tyrosine 
W Trp Tryptophane 
N Asn Asparagine 
Q Gln Glutamine 
D Asp Aspartate 
E Glu Glutamate 
K Lys Lysine 
R Arg Arginine 
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